PRACTICE GUIDANCE

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

Christopher L. Bowlus1 | Lionel Arrivé2 | Annika Bergquist3 | Mark Deneau4 | Lisa Forman5 | Sumera I. Ilyas6 | Keri E. Lunsford7 | Mercedes Martinez8 | Gonzalo Sapisochin9 | Rachna Shroff10 | James H. Tabibian11 | David N. Assis12

1Division of Gastroenterology, University of California Davis Health, Sacramento, California, USA
2Hôpital Saint-Antoine, Paris, France
3Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
4University of Utah, Salt Lake City, Utah, USA
5University of Colorado, Aurora, Colorado, USA
6Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA
7Rutgers University—New Jersey Medical School, Newark, New Jersey, USA
8Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA
9University of Toronto, Toronto, Ontario, Canada
10University of Arizona, Tucson, Arizona, USA
11David Geffen School of Medicine at UCLA, Los Angeles, California, USA
12Yale School of Medicine, New Haven, Connecticut, USA

Correspondence
Christopher L. Bowlus, Division of Gastroenterology, University of California, Davis, 4150 V Street, Suite 3500, Sacramento, CA 95817, USA.
Email: clbowlus@ucdavis.edu

WHAT’S NEW SINCE THE 2010 GUIDELINES?

- Inclusion of guidance for the diagnosis and management of cholangiocarcinoma (CCA) in patients with and without primary sclerosing cholangitis (PSC) (Figures 5, 8, and 9).
- Introduction of the term **relevant stricture**, defined as any biliary stricture of the common hepatic duct or hepatic ducts associated with signs or symptoms of obstructive cholestasis and/or bacterial cholangitis (Table 1).
- In patients with equivocal MRI with cholangiopancreatography (MRI/MRCP) findings, a repeated high-quality MRI/MRCP should be performed for diagnostic purposes. Endoscopic retrograde cholangiopancreatography (ERCP) should be avoided for the diagnosis of PSC (Figure 2).

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIH, autoimmune hepatitis; ALP, alkaline phosphatase; ASIR, age standardized incidence rate; AST, aspartate aminotransferase; BRAF, B-raf proto-oncogene; CA 19-9, carbohydrate antigen 19-9; CCA, cholangiocarcinoma; CRC, colorectal cancer; 3D, three-dimensional; dCCA, distal cholangiocarcinoma; debTACE, drug-eluting bead transarterial chemoembolization; ECOG, Eastern Cooperation Oncology Group; ELF, Enhanced Liver Fibrosis; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasound; FDA, Food and Drug Administration; FGFR2, FGF receptor 2; FISH, fluorescent in situ hybridization; FNA, fine-needle aspiration; FOLFOX, 5-FU and oxaliplatin; 5-FU, 5-fluorouracil; FUT, fucosyltransferases; gem/cis, gemcitabine/cisplatin; GGT, γ-glutamyl transferase; HDG, high-grade dysplasia; IBD, inflammatory bowel disease; ICCA, intrahepatic cholangiocarcinoma; ICD, International Classification of Diseases; IDH, isocitrate dehydrogenase; LN, lymph node; LRT, locoregional therapy; LS, liver stiffness; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; MRCP, MRI retrograde cholangiopancreatography; MRE, magnetic resonance elastography; OCA, obeticholic acid; ORR, overall response rate; OS, overall survival; PBC, primary biliary cholangitis; pCCA, perihilar cholangiocarcinoma; PET, positron emission tomography; PFS, progression-free survival; PREsTO, PSC Risk Estimate Tool; PSC, primary sclerosing cholangitis; RFS, recurrence-free survival; rPSC, recurrent PSC; SBRT, stereotactic body radiation therapy; SCOPE, Sclerosing Cholangitis Outcomes in Pediatrics; TACE, transarterial chemoembolization; TARE, transarterial radioembolization; TE, transient elastography; T1w/T2w, T1-weighted/T2-weighted; UDCA, ursodeoxycholic acid; ULN, upper limit of normal; US, ultrasound.

© 2022 American Association for the Study of Liver Diseases.

Hepatology. 2022;00:1–44.
In patients with PSC without known inflammatory bowel disease (IBD), diagnostic colonoscopy with histological sampling should be performed and may be repeated every 5 years if IBD is not initially detected.

- Colon cancer surveillance should begin at age 15 years in patients with PSC and IBD.

- New clinical risk tools for PSC are available for risk stratification, but probabilities of events in individual patients should be interpreted with caution (Figure 4 and Table 3).

- All patients with PSC should be considered for participation in clinical trials; however, ursodeoxycholic acid (13–23 mg/kg/day) can be considered and continued if well tolerated with a meaningful improvement in alkaline phosphatase (γ-glutamyl transferase in children) and/or symptoms with 12 months of treatment.

- ERCP with biliary brushings for cytology and fluorescent in situ hybridization analysis should be obtained in all patients with suspected perihilar or distal CCA.

- There is a new United Network for Organ Sharing policy regarding standardization of Model for End-Stage Liver Disease exceptions for patients with PSC and recurrent cholangitis.

- Liver transplantation following neoadjuvant therapy is recommended for patients with perihilar CCA <3 cm in radial diameter that is unresectable or arising in the setting of PSC and in the absence of intrahepatic or extrahepatic metastasis (Figure 9).

### Table 1: Definitions in PSC

<table>
<thead>
<tr>
<th>Definition</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSC</td>
<td>Chronic, cholestatic liver disease likely of autoimmune origin characterized by inflammation and fibrosis of intrahepatic and/or extrahepatic bile ducts, leading to the formation of bile duct strictures, and frequently associated with IBD</td>
</tr>
<tr>
<td>Small-duct PSC</td>
<td>Less common variant of PSC that is characterized by typical cholestatic and histological features of PSC but with normal bile ducts on cholangiography</td>
</tr>
<tr>
<td>PSC–AIH overlap</td>
<td>Concurrent diagnostic features of PSC and clinical, biochemical, and histological features of AIH</td>
</tr>
<tr>
<td>Secondary sclerosing cholangitis</td>
<td>Biliary strictures due to identifiable causes that can result in secondary biliary cirrhosis</td>
</tr>
<tr>
<td>IgG4 sclerosing cholangitis</td>
<td>Biliary strictures due to elevated IgG4-positive plasma cells in tissue and serum IgG4 elevation frequently associated with pancreatic involvement</td>
</tr>
<tr>
<td>Dominant stricture</td>
<td>A biliary stricture on ERCP with a diameter of ≤1.5 mm in the common bile duct or of ≤1 mm in the hepatic duct</td>
</tr>
<tr>
<td>High-grade stricture</td>
<td>A biliary stricture on MRI with cholangiopancreatography with &gt;75% reduction in the common bile duct or hepatic ducts</td>
</tr>
<tr>
<td>Relevant stricture</td>
<td>Any biliary stricture of the common bile duct or hepatic ducts associated with signs or symptoms of obstructive cholestasis and/or bacterial cholangitis</td>
</tr>
</tbody>
</table>

This American Association for the Study of Liver Diseases (AASLD) guidance provides a data-supported approach to the diagnosis and management of PSC and CCA. It differs from AASLD guidelines, which are supported by systematic reviews of the literature, formal rating of the quality of the evidence and strength of the recommendations, and, if appropriate, meta-analysis and/or systematic reviews of the evidence. In contrast, this guidance was developed by consensus of an expert panel and provides guidance statements based on formal review and analysis of the literature on the topics, with oversight provided by the AASLD Practice Guidelines Committee at all stages of guidance development. The committee chose to perform a guidance on this topic because a sufficient number of randomized controlled trials were not available to support the development of a
meaningful guideline. In addition to the inclusion of CCA, updates to the 2010 guideline include new terminology for the description of biliary strictures, an emphasis on imaging for diagnosis rather than endoscopic retrograde cholangiopancreatography (ERCP) and liver biopsy, use of prognostic models and noninvasive staging for clinical practice, and comprehensive management of PSC.

EPIDEMIOLOGY OF PSC

Population-based epidemiological studies of PSC have been limited. The majority of studies to date have been based in North America and western Europe, where estimates of incidence and prevalence are approximately 1–1.5 cases per 100,000 person-years and 6–16 cases per 100,000, respectively. Some studies have suggested that the prevalence and incidence of PSC may be increasing. Limited data from other parts of the world suggest a lower PSC prevalence than compared to the United States and northern Europe. Within the United States, African Americans appear to be affected by PSC at rates similar to Whites. Peak incidence of PSC is between the ages of 25 and 45 years, with a median age at diagnosis ranging from 36 to 39 years; but PSC can occur at any age. In children, the incidence rate has been estimated to be 0.2 per 100,000 person-years. Overall, men account for approximately two thirds of patients with PSC; but among patients with PSC without IBD, the male predominance is much lower. Women with PSC are generally older at diagnosis. At least 70%–80% of patients with PSC have concurrent IBD, and the prevalence of PSC in patients with IBD including non-Europeans and children has been estimated to be 0.6%–4.3%. PSC-AIH overlap occurs in up to 35% of children and 5% of adults with PSC. Studies employing universal liver biopsy or cholangiography screening of patients with IBD have yielded PSC prevalence of 8.1%–9.0% in adults and 15.1% in children, suggesting that there may be tens of thousands of undiagnosed patients in North America alone.

ETIOLOGY OF PSC

Multiple simultaneous mechanisms appear to lead to PSC and its progression (Figure 1). There is a clear genetic predisposition involving human leukocyte antigen (HLA) variants, and many additional non-HLA loci have been implicated. Less is known about environmental risks of PSC other than a possible link to nonsmoking. Evidence suggests that IBD may drive PSC rather than this being an epiphenomenon. A few studies have demonstrated an impaired gut barrier in PSC, and an expanding body of evidence has developed on the dysbiosis of the intestinal gut microbial community in PSC. Aberrant trafficking of gut lymphocytes and peribiliary inflammation, which consists of macrophages, eosinophils, and T cells, have been proposed to induce activation of biliary epithelial cells and peribiliary inflammation, which consists of macrophages, eosinophils, and T cells. Unconventional T cells including mucosa-associated invariant T and γδ T cells important for recognition of bacterial pathogens have also been suggested to play a role in PSC and localize to areas of fibrosis. IL-17 production by γδ T cells has been implicated in the development of cholestatic fibrosis and inflammation in animal models and in PSC as well. The fibrosis of large bile ducts in PSC is associated with peribiliary gland hyperplasia and activation of peribiliary mesenchymal cells, which acquire a myofibroblast phenotype. Strictures of large bile ducts, reduced bile flow, increased biliary pressure, and alterations in bile composition associated with cholestasis may further drive disease progression. Still unresolved is why immunosuppressive therapy and colectomy do not appear to alter the disease course, perhaps indicating that some mechanisms are involved in the initiation of PSC but have little influence on disease progression.

DIAGNOSIS OF PSC

PSC should be considered in all patients with cholestasis, especially in the setting of IBD. The diagnosis is based on characteristic strictures on cholangiography. Careful exclusion of secondary sclerosing cholangitis is required, especially in the absence of IBD (Table 2). Small-duct PSC is diagnosed based on histological findings that are typical or compatible with PSC in the presence of a normal cholangiogram (see “Histology” section below). In cases of suspected small-duct PSC without IBD, variants of the ATP binding cassette subfamily B member 4, also known as multidrug resistance protein 3, gene should be excluded. In the presence of clinical, biochemical, and histologic features of AIH and cholangiographic findings of PSC, the diagnosis of PSC-AIH overlap, also known as PSC with overlapping features of AIH, should be considered. Conversely, PSC-AIH overlap should be considered in patients with AIH and IBD, unexplained cholestatic laboratory findings, or nonresponse to conventional glucocorticoid therapy.
Symptoms

Nearly half of adult patients with PSC present with constant or intermittent symptoms, and another 22% develop symptoms within 5 years of diagnosis. Pruritus and abdominal pain can fluctuate depending on the presence of biliary obstruction and/or acute cholangitis. Emotional distress can be exacerbated by anxiety about the idiopathic nature of the disease, lack of effective therapy, and elevated cancer risk. Assessment of PSC symptoms is complex in patients with IBD, which itself causes symptoms such as abdominal pain and fatigue. There is a growing interest in measuring PSC symptoms through patient-reported outcome measures (PROM). Two recent PROMs were developed specifically for patients with PSC: the PSC PRO and the Simple Cholestatic Complaints Score; however, they require further validation prior to routine clinical use.

Biochemical and serological tests

Biochemical markers are sensitive but not specific for the diagnosis of PSC. A cholestatic biochemical profile with elevated liver enzymes, such as alkaline phosphatase (ALP) and γ-glutamyl transferase (GGT), is seen in about 75% of patients. Notably, elevated aminotransferases occur frequently and do not necessarily suggest overlapping AIH, unless they are predominantly or more than 5 times the upper limit of normal (ULN). Notably, elevated aminotransferases occur frequently and do not necessarily suggest overlapping AIH, unless they are predominantly or more than 5 times the upper limit of normal (ULN). However, precise diagnostic criteria for PSC-AIH overlap have not been established.

Detection of serum autoantibodies, including antinuclear, anti-smooth muscle, and perinuclear antineutrophil antibodies, in patients with PSC is highly variable,
likely representing an immune dysregulation state. In contrast to primary biliary cholangitis (PBC) and AIH, autoantibodies have minimal diagnostic implications for PSC. Elevation of serum IgG4 occurs in up to 15% of patients with PSC, but the clinical significance is unclear. High-titer IgG4 (> 5.6 g/L) is rare and suggests a diagnosis of IgG4-sclerosing cholangitis, whereas an IgG4/IgG1 ratio < 0.24 can exclude IgG4-sclerosing cholangitis when the serum IgG4 is 1.4–2.8 g/L.

**Imaging**

MRI with cholangiopancreatography should be the first diagnostic imaging modality in patients with suspected PSC. Imaging should be performed on a scanner with a minimum of a 1.5-Tesla field strength. T2 weighted (T2w), three-dimensional (3D) MRI retrograde cholangiopancreatography (MRCP) with 1-mm slices is preferred to two-dimensional MRCP, and axial imaging should include T1-weighted (T1w) and T2w sequences. Enhancement with an extracellular or hepatobiliary contrast agent is recommended at diagnosis and when imaging is done in response to a change in clinical status or due to concerns for CCA. There is insufficient evidence to recommend one type of contrast agent over another. A high-quality study is one in which there is no artifact or blurring and third-order biliary branches and beyond can be delineated. Before the advent of MRI/MRCP, ERCP was regarded as the gold standard in diagnosing PSC. However, ERCP is associated with serious complications and should only be performed for therapeutic intervention or tissue sampling. Multiple studies have shown that MRI/MRCP has comparable diagnostic accuracy to ERCP. Importantly, in a patient with a high pretest probability of PSC, there remains a 30% probability of PSC even if the MRCP is negative. Thus, in the setting of an MRI/MRCP that is suboptimal or equivocal, the study should be repeated, preferably at an experienced imaging center using 3D MRCP reconstruction. Transabdominal ultrasound (US) is usually nondiagnostic, although bile duct wall thickening and/or focal bile duct dilatations may be demonstrated. CT is limited in the assessment of strictures of intrahepatic bile ducts. A normal US or CT is not sufficient to rule out PSC.

MRI/MRCP features of PSC are highly variable, probably related to the stage of the disease process (Figure 3). Specific terms such as stenosis, stricture, and dilatation are preferred rather than imprecise descriptions such as beaded, pruned-tree appearance, or irregularity of bile ducts. Early in the course of the disease, diffusely distributed, short, intrahepatic strictures alternating with normal or slightly dilated segments are demonstrated. Contrast-enhanced T1w images may demonstrate biliary wall thickening and mural contrast enhancement of the biliary ducts. As fibrosis progresses, the strictures worsen and the ducts become obliterated. With worsening of PSC, focal signal abnormalities of the liver parenchyma on T2w and diffusion-weighted images suggest cholestasis and inflammation. Fibrosis may be demonstrated by focal parenchymal atrophy and liver dysmorphism, defined as atrophy of a hepatic lobe, lobulations of the liver surface, and/or increase of the caudate:right lobe ratio.

A dominant stricture has been defined as a stenosis with a diameter of ≤1.5 mm in the common bile duct or ≤1 mm in the hepatic duct by ERCP. However, in clinical practice, the term has been used without clear consensus on this definition. The term dominant stricture should not be used in MRI reports because of suboptimal spatial resolution of MRI/MRCP and basic differences with ERCP, which is performed with high-pressure injection. A similar term for common bile duct and hepatic duct strictures observed on MRI is high-grade stricture, which is defined by a reduction in the lumen by >75%.

### Table 2: Etiologies of secondary sclerosing cholangitis

<table>
<thead>
<tr>
<th>Category</th>
<th>Etiology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infectious</td>
<td>HIV-related cholangiopathy, Recurrent pyogenic cholangitis, Cholangitis lenta or subacute nonsuppurative cholangitis, Parasitic cholangiopathy, Hydatid cyst, Echinococcosis, Clonorchiasis and opisthorchiasis, Ascariasis, Fascioliasis, Schistosomiasis</td>
</tr>
<tr>
<td>Ischemic</td>
<td>Critically ill patients, Hereditary hemorrhagic telangiectasis, Intra-arterial chemotherapy, Hepatic artery thrombosis</td>
</tr>
<tr>
<td>Malignant</td>
<td>Cholangiocarcinoma, Diffuse intrahepatic metastasis, Langerhans cell histiocytosis, Lymphoma</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>Eosinophilic cholangitis, Hepatic inflammatory pseudotumor, IgG4-associated cholangitis, Mast cell cholangiopathy, Sarcoidosis</td>
</tr>
<tr>
<td>Anatomic</td>
<td>Choleodocholithiasis, Intrahepatic lithiasis, Cystic fibrosis liver disease, Surgical biliary trauma, Anastomotic stricture, Portal hypertensive biliopathy, Recurrent pancreatitis, Sickle cell cholangiopathy, Choledochal cyst</td>
</tr>
<tr>
<td>Drug-induced</td>
<td>Immunotherapy with checkpoint inhibitors, Pembrolizumab, Nivolumab, Atezolizumab</td>
</tr>
</tbody>
</table>

**TABLE 2**

Etiologies of secondary sclerosing cholangitis

<table>
<thead>
<tr>
<th>Etiology</th>
<th>Table 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-related cholangiopathy</td>
<td>Recurrent pyogenic cholangitis</td>
</tr>
<tr>
<td>Cholangitis lenta</td>
<td>Subacute nonsuppurative cholangitis</td>
</tr>
<tr>
<td>Parasitic cholangiopathy</td>
<td>Hydatid cyst</td>
</tr>
<tr>
<td>Echinococcosis</td>
<td>Clonorchiasis and opisthorchiasis</td>
</tr>
<tr>
<td>Ascariasis</td>
<td>Fascioliasis</td>
</tr>
<tr>
<td>Schistosomiasis</td>
<td></td>
</tr>
<tr>
<td>Ischemic</td>
<td>Critically ill patients</td>
</tr>
<tr>
<td>Hereditary hemorrhagic telangiectasis</td>
<td>Intra-arterial chemotherapy</td>
</tr>
<tr>
<td>Hepatic artery thrombosis</td>
<td></td>
</tr>
<tr>
<td>Malignant</td>
<td>Cholangiocarcinoma</td>
</tr>
<tr>
<td>Diffuse intrahepatic metastasis</td>
<td>Langerhans cell histiocytosis</td>
</tr>
<tr>
<td>Lymphoma</td>
<td></td>
</tr>
<tr>
<td>Autoimmune</td>
<td>Eosinophilic cholangitis</td>
</tr>
<tr>
<td>Hepatic inflammatory pseudotumor</td>
<td>IgG4-associated cholangitis</td>
</tr>
<tr>
<td>Mast cell cholangiopathy</td>
<td>Sarcoidosis</td>
</tr>
<tr>
<td>Anatomic</td>
<td>Choleodocholithiasis</td>
</tr>
<tr>
<td>Intrahepatic lithiasis</td>
<td>Cystic fibrosis liver disease</td>
</tr>
<tr>
<td>Surgical biliary trauma</td>
<td>Anastomotic stricture</td>
</tr>
<tr>
<td>Portal hypertensive biliopathy</td>
<td>Recurrent pancreatitis</td>
</tr>
<tr>
<td>Sickle cell cholangiopathy</td>
<td>Choledochal cyst</td>
</tr>
<tr>
<td>Drug-induced</td>
<td>Immunotherapy with checkpoint inhibitors</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>Nivolumab</td>
</tr>
<tr>
<td>Atezolizumab</td>
<td></td>
</tr>
</tbody>
</table>
for a term to describe a stricture that has clinical relevance but may not meet the strict criteria of a dominant or high-grade stricture. Therefore, the term relevant stricture is introduced to refer to any biliary stricture of the common bile duct or hepatic ducts associated with signs or symptoms of obstructive cholestasis and/or bacterial cholangitis (Table 1).

Histology

Modern imaging modalities have decreased the need for a liver biopsy to diagnose PSC. Liver biopsy should be considered if there is concern for small-duct PSC or overlap with AIH. Concentric “onion skin” periductal fibrosis is an infrequent histological feature that can be seen in PSC and other obstructive cholangiopathies. Typical histologic features of PSC include periductal fibrosis and fibro-obliterative duct lesions, whereas compatible features include bile duct loss, ductular reaction (also referred to as ductular proliferation), a biliary pattern of interface activity, and chronic cholestatic changes in periportal hepatocytes. The presence of these features should be the basis for the diagnosis of small-duct PSC when the MRCP is normal. Histologic features of AIH, including lymphoplasmacytic interface hepatitis in the setting of PSC, may signify an overlap with AIH.

IBD

Over 70% of patients with PSC have IBD, with two thirds diagnosed as ulcerative colitis and the other third as Crohn’s disease or indeterminate colitis. IBD in PSC (PSC-IBD) is more frequently localized in the right colon and notable for backwash ileitis. In children, 5% of patients with PSC without a prior diagnosis of IBD and no symptoms were found to have quiescent colitis. In addition, histological evidence of IBD without endoscopic changes of IBD is frequent. Therefore, patients with PSC, including children, who do not have known IBD should undergo ileocolonoscopy with biopsies at the time of PSC diagnosis to screen for asymptomatic colitis. If no colitis is detected, ileocolonoscopy with biopsies should be considered at 5-year intervals or if symptoms suggestive of IBD occur because IBD may develop after PSC diagnosis.
The clinical course of IBD in patients with PSC-IBD is often less aggressive with less frequent need for immunosuppression. Patients with PSC are prone to developing pouchitis after colectomy with ileoanal anastomosis, and patients with portal hypertension have an increased risk of peristomal and stomal varices.

**Guidance statements**

1. In patients with suspected PSC, a 3D MRI/MRCP with T1w and T2w axial images and contrast enhancement should be obtained to evaluate for cholangiographic features of PSC, including intrahepatic and/or extrahepatic strictures alternating with normal or slightly dilated segments.
2. In patients with suspected PSC and a normal, high-quality MRI/MRCP, liver biopsy should be considered to rule out small-duct PSC. Patients with an equivocal MRI/MRCP should be referred to an experienced center for consideration of a repeat high-quality MRI/MRCP or liver biopsy. A repeat MRI/MRCP may be considered in 1 year if the diagnosis remains unclear.
3. ERCP should be avoided for the diagnosis of PSC.
4. In all patients with possible PSC, serum IgG4 levels should be measured to exclude IgG4-sclerosing cholangitis.
5. A liver biopsy should not be performed in patients with typical cholangiographic findings on MRI/MRCP, except when there is concern for AIH overlap.
6. Ileocolonoscopy with biopsies should be performed in patients with a new diagnosis of PSC and no previous diagnosis of IBD. In patients without IBD, subsequent ileocolonoscopy should be considered at 5-year intervals or whenever symptoms suggestive of IBD occur.

**NATURAL HISTORY OF PSC**

PSC is a heterogenous disease with a variable course that can be complicated not only by cirrhosis but also by bacterial cholangitis, CCA, and CRC. Most patients have slowly progressive liver disease with increasing hepatobiliary fibrosis, biliary strictures, intermittent bacterial cholangitis, and eventually cirrhosis and end-stage liver disease. Median time to death or liver transplantation (LT) was reported to be as low as 9 years in studies from referral centers, but more recent population-based studies estimate it to be 21 years or longer. As an increasing proportion of patients are transplanted, deaths from end-stage liver disease
have decreased, but deaths from CCA appear to be unchanged.\textsuperscript{150} PSC is increasingly diagnosed in the early stage,\textsuperscript{150,151} which is likely due to increased awareness of PSC, use of MRI/MRCP, and screening of liver function tests in the general population and in patients with IBD. However, many people with PSC likely remain undiagnosed.\textsuperscript{40,41,152–154}

Patient demographics and PSC phenotype influence disease progression. Younger age at diagnosis and female sex are associated with better outcomes.\textsuperscript{20} Patients diagnosed under age 20 have a 2.5 times longer median transplant-free survival and a 17 times lower rate of CCA compared to patients diagnosed over age 60.\textsuperscript{155} Patients with PSC-AIH overlap are reported to have a reduced risk for LT or death compared to those with PSC alone.\textsuperscript{20} Small-duct PSC also has a more favorable prognosis with longer time until liver cirrhosis and lower risk for hepatobiliary malignancy.\textsuperscript{20,155} Twenty-three percent of patients with small-duct disease are reported to develop large-duct disease over 5–14 years.\textsuperscript{135} Whether small-duct PSC represents a separate entity or an early/mild form of PSC remains controversial. Nonetheless, patients with small-duct PSC should be monitored by MRI/MRCP every 3–5 years for the development of large-duct disease.

Presence of symptoms and high ALP levels are associated with a worse prognosis. At the time of diagnosis and in earlier stages, patients are often asymptomatic and can remain so despite disease progression.\textsuperscript{103,154} Although ALP often fluctuates during the disease course,\textsuperscript{151,155} persistently normal/low levels (ALP < 1.5 × ULN) are associated with better prognosis.\textsuperscript{157–161} ALP is invalid in children due to wide fluctuations in normal values with age and bone growth, and instead GGT should be used. Like in adults, high rates of spontaneous normalization of GGT early in the disease course are seen in children, and persistently normal/low levels (GGT < 50 U/L) are associated with better prognosis.\textsuperscript{162,163}

### Progressive fibrosis/cirrhosis

Accumulation of hepatobiliary fibrosis in PSC appears to be slow. Over the course of a 2-year clinical trial of simtuzumab, direct and indirect measures of fibrosis were stable in most patients; and Ishak fibrosis stage on serial liver biopsies improved in 29%, remained unchanged in 34%, and worsened in 37%.[164] Similarly, among 141 children with PSC who had serial liver biopsies 12–18 months apart, Batts-Ludwig fibrosis stage improved in 17%, remained unchanged in 64%, and worsened in 19%,\textsuperscript{165} confirming the results of smaller studies demonstrating no significant change in fibrosis stage over 1–5 years.\textsuperscript{166–174}
Cholangitis/gallstones

Although a consensus on the criteria required to diagnose bacterial cholangitis in patients with PSC is lacking, case series report that approximately 6% of patients with PSC have bacterial cholangitis at diagnosis and that nearly 40% experience this complication during the disease course. During a clinical trial, bacterial cholangitis was the most common disease-related complication, occurring in 12% of patients over 2 years. The importance of bacterial cholangitis for disease progression remains unclear. A positive bacterial culture of bile in the presence of a dominant stricture was not associated with a worse prognosis, and bacterial cholangitis was not associated with survival among patients with PSC awaiting LT. In contrast, Candida in bile is a poor prognostic sign.

Gallstones, sludge, chronic cholecystitis, and/or gallbladder polyps occur in near half of patients with PSC. Intrahepatic bile duct calculi are present in 8% of patients, and some of these patients require repeated interventions with ERCP when stones and sludge contribute to bile duct obstruction.

Biliary strictures

Development of biliary strictures may occur at all levels in the biliary tree, but strictures of the common bile duct and common hepatic duct have more significant effects on the natural history of PSC. Dominant strictures are present in up to half of patients at the time of diagnosis and may present without symptoms or with increased cholestasis, jaundice, pruritus, and/or fevers. Up to 45% of patients with PSC will develop dominant strictures. Patients with the disease limited to intrahepatic ducts seem to have a better outcome. High-grade strictures with prestenotic dilatation at MRI/MRCP are associated with poorer outcomes. In addition, dominant stricture on ERCP or a rapid progression of a stricture at MRI/MRCP increases the risk of CCA. Further, the presence of a dominant stricture, even in the absence of bile duct malignancy, significantly reduces survival.

Malignancy

CCA

CCA can occur any time during the disease course, with the highest risk (2.5%) reported within the first year after PSC diagnosis and thereafter 1%–1.5% per year. In one large population-based study, the cumulative risk of CCA after 10, 20, and 30 years of PSC was 6%, 14%, and 20%, respectively. Compared to the general population, the risk of CCA is 160–400 times greater. In the largest population-based study (N = 2588), the risk of CCA was 28 times greater in patients with PSC-IBD compared to patients with IBD without PSC. Rapid worsening of symptoms, cholestasis, or weight loss should raise the suspicion of CCA, although some patients with CCA can be completely asymptomatic. In the presence of cirrhosis, the signs and symptoms of CCA may not differ from those of end-stage liver disease.
The most consistent risk factor for CCA is older age. CCA is rarely diagnosed in the pediatric population or in those with small-duct PSC. Other risk factors include male sex, dominant stricture, and comorbidity with IBD, along with elevated bilirubin levels. The impact of environmental factors such as smoking and alcohol is uncertain. Like other causes of cirrhosis, PSC cirrhosis increases the risk for HCC. However, the risk is lower than for CCA, with one large study reporting HCC in 2.4% during nearly 10 years of follow-up.

Gallbladder cancer

Gallbladder cancer in PSC is 9–78 times greater compared to the general population. Gallbladder polyps may be a premalignant stage and are present in 6%–16% of patients with PSC. The risk for malignant development of a gallbladder polyp increases with size, but evidence for a specific size cutoff for malignancy is lacking. In one study, small polyps < 10 mm were reported to be a transient finding or were stable in size over time, and only 6% increased in size at follow-up. Underlying malignancy in polyps < 5 mm is low. The prevalence of adenocarcinoma in cholecystectomy specimens from patients with PSC and a gallbladder polyp or mass lesion varies between 18% and 56%.

CRC

The risk of CRC in PSC is 5–12 times greater compared to the general population and 4–5 times greater compared to patients with IBD without PSC, with a tendency toward right-sided lesions and younger age at onset. A meta-analysis of 1022 patients from 16 studies estimated the risk of CRC/dysplasia to be 3 times greater in patients with PSC-IBD compared with IBD alone. Early studies found a cumulative incidence of CRC in PSC-IBD of up to 40% after 20 years of disease, but more recently the incidence rates of CRC in PSC-IBD seem to have decreased, with one study reporting 5-year and 10-year CRC incidence rates of 7% and 9%, respectively. Children develop CRC at similar rates as adults, with 5% affected at 10 years. In addition, patients with PSC more frequently have endoscopically invisible dysplasia; and when low-grade dysplasia is present, it progresses to high-grade dysplasia (HGD) or CRC more rapidly compared to IBD alone.
Young age at IBD diagnosis is a risk factor for CRC in PSC-IBD. Children with PSC and IBD onset before age 6 had a greater risk of CRC than those diagnosed in their teenage years. Chronic inflammation may contribute to the CRC risk and is often underestimated in PSC, in both adults and children. The risk of CRC in patients with PSC without IBD relative to the average-risk population is unknown, but in one study of 590 patients with PSC, 20 developed CRC and all but one had IBD.

**Staging of PSC and prognostic tools**

The characteristics of PSC present challenges to creating distinct definitions of disease stages, and formal criteria do not yet exist. Unlike other liver diseases, clinical complications in PSC are not isolated to those who have developed cirrhosis, and severe symptomatic biliary strictures in PSC can occur before the onset of advanced fibrosis or cirrhosis. CCA and CRCs can occur at any disease stage. Additionally, PSC progression is variable; some patients at a low fibrosis stage may progress rapidly, and some patients with advanced fibrosis may remain asymptomatic and stable for many years. In clinical practice, risk assessment for clinical events such as hepatic decompensation or transplant-free survival, rather than disease staging, may be useful for guidance on follow-up and management strategies.

**Liver biopsy**

Advanced fibrosis in PSC is associated with worse prognosis. The Nakanuma, Ishak, and Batts-Ludwig staging systems were each associated with transplant-free survival and time to LT with similar prognostic ability. In the prospective simtuzumab trial, baseline Ishak fibrosis stage was strongly correlated with 2-year outcomes. Liver histology in PSC is hampered by a large sampling variability because high-grade strictures and cholestasis may lead to unequal distribution of fibrosis throughout the liver. A blinded review of paired biopsies obtained from the same liver location showed that Batts-Ludwig stage differed by one stage in 16% and two stages in 11% of patients with PSC. Therefore, liver biopsy is not recommended for staging of fibrosis or prognostication in PSC outside of the clinical trial setting.

**Liver stiffness**

Liver stiffness (LS) measurements in PSC by transient elastography (TE) or magnetic resonance elastography (MRE) are reasonably accurate for estimation of liver fibrosis and correlate with long-term patient outcomes. Cutoff values of 9.6 kPa by TE for extensive fibrosis (F3) and 14.4 kPa for cirrhosis (F4) have a diagnostic accuracy > 0.80. Similarly, LS of 4.6 kPa by MRE has an area under the receiver-operator curve of 0.82 for cirrhosis. Higher LS by TE or MRE has been associated with increasing risk of clinical outcomes. Changes of LS over time increase slowly through early stages of fibrosis and then exponentially as fibrosis progresses to cirrhosis. Importantly, LS is affected not only by fibrosis but also by blood flow, inflammation, and cholestasis. In PSC, the impact of transient episodes of cholestasis due to biliary obstruction may influence these results. The optimal frequency and clinical utility of repeated LS measurements remains unclear and needs further study. In 204 patients who underwent serial MRE a median of 1.1 years apart, mean change in LS was only 0.05 kPa/year overall. Larger changes in LS predicted worse clinical outcomes, with the highest risk of hepatic decompensation seen with LS worsened by >0.34 kPa/year. Mean LS by TE was unchanged over 2 years for nearly all patients in the simtuzumab trial.

**Serum fibrosis tests**

The Enhanced Liver Fibrosis (ELF) test is a composite of three serum biomarkers of hepatobiliary fibrosis: hyaluronic acid, procollagen III amino-terminal peptide, and tissue inhibitor of metalloproteinase 1. ELF is strongly associated with transplant-free survival in PSC and may be useful as a surrogate marker in clinical trials. Stable versus worsened ELF from baseline to Week 12 in a clinical trial was associated with more favorable outcomes, regardless of treatment. ELF had less variability on serial measurements than ALP. However, the ELF test is not widely available commercially. Serum matrix metalloproteinase 7 was more accurate than GGT or ALP in distinguishing PSC from AIH in children and correlated with histopathologic stage of fibrosis and MRE. Aspartate aminotransferase (AST) to platelet ratio index correlates with fibrosis stage, TE, and clinical outcomes in adults and children. Fibrosis-4 index, a score based on patient age, AST, alanine aminotransferase (ALT), and platelet count designed to assess the need for biopsy in chronic hepatitis C, performs reasonably well in PSC, though it is inferior to LS measurement.

**Cholangiography**

Despite recent advances in diagnostic imaging, the interpretation of MRI/MRCP examinations of patients with PSC remains challenging, with high interreader disagreement. The MRI/MRCP-based Analí scores summarize intrahepatic ductal dilation, dysmorphism, and portal hypertensive features without contrast.
and hepatic dysmorphism and parenchymal enhancement with contrast. These scores are associated with long-term outcomes in PSC and may offer complementary prognostic value with LS. Relative contrast enhancement of hepatic parenchyma 20 min after injection is associated with outcomes as well as Mayo risk and Amsterdam–Oxford clinical scores and fibrosis stage on biopsy. Scoring of severity of intrahepatic and extrahepatic stricturing on ERCP correlated with transplant-free survival and was externally validated. In children, the Mayo risk classification applied to MRCP, based on the worst-affected intrahepatic and extrahepatic regions, was predictive of outcome. However, MRCP and ERCP may correlate poorly with one another. Objective, software-based analyses of MRCP data may offer additional insights, but they are not yet validated or available clinically.

Clinical prediction tools or models

Noninvasive risk assessment using routinely obtained biochemistry and imaging is possible with clinical prognostic and risk stratification models that have been created for PSC. Patients with a lower risk of progression, especially those who also have a low fibrosis stage, are highly unlikely to experience clinical events in the next 5 years. Conversely, patients with a higher risk of progression, such as those with advanced fibrosis, are more likely to experience complications. Patients, families, and clinicians can use this information to discuss frequency of follow-up, weigh the risks and benefits of future treatment options, and consider the appropriateness of clinical trials. However, specific probabilities of events should be interpreted with caution in the individual patient.

Older models based on physical examination (i.e., splenomegaly) or data obtained from liver biopsy have been replaced by newer models using objective, quantitative data. The Revised Mayo Risk Score predicts short-term mortality and has traditionally been the most widely used. It has several shortcomings including low utility in early stages of the disease, lack of utility in small-duct and AIH-overlap phenotypes, inability to predict long-term outcomes, inability to predict nonmortality endpoints, and poor utility in clinical trials. Four more recent models derived from larger, more population-based cohorts and all-inclusive of serum bilirubin, albumin, and platelet count have outperformed the Mayo risk score (Table 3). The models accurately classify patients as lower versus higher risk of clinical outcomes such as hepatic decompensation or transplant-free survival, though none of the prognostic models used in adults can assess the risk for or predict CCA, which can occur at any disease stage. Patient-specific probabilities of events provided by the models should also be interpreted with caution, and each model may not be appropriate for all patients due to inclusions and exclusions of the individual data sets (Figure 4). In addition, the models are primarily intended for prediction at PSC diagnosis. The Sclerosing Cholangitis Outcomes in Pediatrics (SCOPE), PSC Risk Estimate Tool (PREsTO), and Amsterdam–Oxford models showed similar accuracy when using data from 2 years after diagnosis; but more data are needed on the validity and clinical value of repeated measurements. For patients who have end-stage liver disease, the Model for End-Stage Liver Disease (MELD) or Pediatric End-Stage Liver Disease score is most appropriate.

 Guidance statements

1. Patients with small-duct PSC should be monitored by MRI/MRCP every 3–5 years for the development of large-duct disease.
2. Risk stratification and fibrosis staging should be done at diagnosis of PSC and regularly during follow-up. Clinical risk tools can be considered for this purpose, but specific probabilities of events should be interpreted with caution in the individual patient.
3. LS measurement by TE or MRE is currently the preferred method for estimation of fibrosis stage in PSC.
4. Liver biopsy is not recommended for fibrosis staging in clinical practice.

MANAGEMENT OF PSC

At present, there is no approved medication for the treatment of PSC, and none has been proven to halt disease progression. Management therefore revolves around recognizing and treating the complications of PSC when they develop. Ultimately, LT is recommended for patients with refractory cholangitis and/or decompensated cirrhosis.

Medical management

Many choleretic, immunosuppressive, antimicrobial, and antifibrotic agents have been investigated to treat PSC; but no drug has been shown to alter its natural history or offer any clinical benefit. Prednisone, methotrexate, azathioprine, penicillamine, tacrolimus, colchicine, nicotine, mycophenolate mofetil, pentoxifylline, budesonide, metronidazole, silymarin, pirfenidone, and etanercept have failed to demonstrate evidence of efficacy. Importantly,
clinical trials in PSC are challenging to conduct due to the uncertainty regarding its pathogenesis, the slow progressive nature of the disease, significant patient heterogeneity, and a lack of established clinical trial endpoints.\textsuperscript{[243]}

Due to the low disease prevalence, referral of patients for consideration in clinical trials is imperative to successful drug development.

**Ursodeoxycholic acid**

Ursodeoxycholic acid (UDCA) is the most studied drug in PSC. It is a hydrophilic 3,7-dihydroxy bile acid. Potential benefits in PSC include increasing bile flow, direct and indirect cytoprotection, stabilization of cell membranes, immunomodulation, dilution of the hydrophobic bile acid pool, and down-regulation of apoptosis. In addition, UDCA has anti-inflammatory and antisenescent properties.\textsuperscript{[244]} Evidence for its efficacy in PSC has not been consistent. Studies using low-dose UDCA (13–15 mg/kg/day) have shown improvement in ALP by 12 months but no improvement in liver histology or transplant-free survival.\textsuperscript{[169]} Evidence for the use of intermediate-dose UDCA (17–23 mg/kg/day) has been inconclusive.\textsuperscript{[171,245]} In the largest study to date, UDCA at a dose of 17–23 mg/kg did not achieve statistical significance for reduction in the need for LT, CCA, or overall mortality.\textsuperscript{[246]} This study was underpowered, however, with only 63% of predicted patients enrolled. A multicenter controlled trial of 150 patients treated with high-dose UDCA (28–30 mg/kg/day) or placebo was terminated early due to futility.\textsuperscript{[229]} On post hoc analysis, UDCA was associated with an increased risk of serious adverse events.\textsuperscript{[247]} Furthermore, in patients with PSC and ulcerative colitis, high-dose UDCA was associated with an increased risk of colorectal neoplasia.\textsuperscript{[248]} Therefore, high-dose UDCA is not recommended and should not be prescribed.

The prior 2010 AASLD guidelines on PSC recommended against the use of UDCA as medical therapy.\textsuperscript{[249]} However, recent data in adults have shown that meaningful reductions in ALP have been associated with significantly better outcomes, including (1) reduction of ALP to <1.5 × ULN, (2) 40% reduction or normalization of ALP, and (3) normalization of ALP.\textsuperscript{[157–159,250]} In children, a 75% reduction in GGT or a GGT < 50 IU was associated with the best outcomes.\textsuperscript{[163,165]} In addition, UDCA withdrawal has been associated with increases in fatigue, pruritus, liver biochemistries, and Mayo PSC Risk score.\textsuperscript{[251,252]} Given these recent data demonstrating the potential benefits of ALP/GGT reduction or normalization, one approach, particularly for patients who are ineligible or uninterested in clinical trials, is to consider treatment with UDCA. Because ALP and GGT can normalize spontaneously, patients should be observed for 6 months prior to starting UDCA to confirm that the elevations are persistent.\textsuperscript{[165]} Although UDCA doses of 28 mg/kg/day or greater should be avoided, there are no data to support lower-dose (13–15 mg/kg/day) or intermediate-dose (17–23 mg/kg/day) UDCA over the other. Therefore, patients with a persistently elevated ALP/GGT can be considered for UDCA treatment at 13–23 mg/kg/day, and treatment can be continued if UDCA is tolerated and there is a meaningful reduction or normalization of ALP (GGT in children) or improvement of symptoms with 12 months of treatment.

**Antibiotics**

Given the potential role of gut dysbiosis in biliary injury,\textsuperscript{[253,254]} modulation of the gut microbiome with antibiotics as a treatment of PSC has gained wide interest. Multiple antibiotics have been investigated, including minocycline, metronidazole, and rifaximin, with inconclusive results.\textsuperscript{[172,255–257]} The most studied antibiotic is oral vancomycin, but there have been only two small randomized studies in adults with PSC. In one study, eight patients were treated with 125 mg orally four times daily, and seven patients were treated with 250 mg orally four times daily with an improvement from baseline to 12 weeks reported in the higher-dose group.\textsuperscript{[255]} A second randomized trial of 29 patients, 18 treated with oral vancomycin 125 mg four times daily, suggested a reduction in PSC Mayo risk score.\textsuperscript{[258]} Open-label studies in children and adults have shown improvements in liver enzymes,\textsuperscript{[259,260]} but a more recent study did not support any benefit.\textsuperscript{[166]} In the largest study to date, 264 patients from the Pediatric PSC Consortium were retrospectively analyzed.\textsuperscript{[166]} Neither treatment with UDCA nor oral vancomycin was associated with improvements in biochemistries, fibrosis, or clinical outcomes compared to observation. Given the potential for antibiotic resistance and lack of adequate randomized clinical trials, at this point, there is insufficient evidence to recommend the use of oral vancomycin for the treatment of PSC. A clinical trial investigating vancomycin is currently ongoing (NCT03710122). The use of vancomycin and other antibiotics for the management of associated IBD is outside the scope of this guidance.

**Drugs in development**

Future therapies are being investigated. Cilofexor is a nonsteroidal farnesoid X receptor (FXR) agonist that, in a Phase 2 randomized controlled trial of patients with PSC with an elevated ALP and without cirrhosis, induced a 21% reduction in ALP after 12 weeks of treatment with the 100-mg daily dose.\textsuperscript{[261]} In a Phase 2 randomized controlled trial of nor-UDCA, a side chain–shortened homolog of UDCA, a 1500-mg daily dose similarly reduced ALP by 26% after 12 weeks.\textsuperscript{[262]} Obeticholic acid (OCA), an FXR agonist approved
for the treatment of PBC, reduced ALP 14%–25% in a randomized controlled trial in PSC depending upon the dose of OCA (1.5–3 mg daily or 5–10 mg daily) and concomitant use of UDCA.Fibrates, including bezafibrate, a pan–peroxisome proliferator–activated receptor (PPAR) agonist that has shown efficacy in PBC but is not available in the United States, and fenofibrate, have demonstrated encouraging results in PSC; however, randomized clinical trials are lacking. Finally, a recent nationwide case–control study in Sweden found that statin use was associated with a reduced risk of all-cause mortality (HR, 0.68; 0.54–0.88) and death or LT (HR, 0.50; 0.28–0.66), leading to an ongoing randomized controlled trial of simvastatin.

PSC-AIH overlap and IgG4 disease
Immunosuppression should be considered for the management of patients with predominant manifestations of AIH per AASLD guidelines and patients with IgG4 sclerosing cholangitis.

Bacterial cholangitis
Bacterial cholangitis is common in patients with PSC and can be the first presentation of the disease in up to 6%. In addition, bacterial cholangitis may occur after ERCP. Bacterial cholangitis should be treated with antibiotics; in rare cases, patients need to be on rotating antibiotics to prevent recurrent episodes. After an initial episode of bacterial cholangitis, MRCP should be considered to assess for the presence of a relevant stricture. Patients with acute bacterial cholangitis who have an inadequate response to medical management should be referred for therapeutic ERCP.

Portal hypertension/cirrhosis
Because PSC is a progressive disease, many patients will eventually develop end-stage liver disease. The management of portal hypertension and cirrhosis is generally the same in PSC compared to other chronic liver diseases, though PSC is associated with noncirrhotic portal hypertension, and infection of a transjugular intrahepatic portosystemic shunt may rarely occur in patients with chronically infected bile ducts. However, like other forms of cirrhosis, Baveno-VI criteria (LS <20 kPa and platelet count >150,000/mm3) are accurate at predicting the absence of varices needing treatment in patients with PSC in order to avoid unnecessary esophagogastroduodenoscopy (EGD) screening. In a study of 80 patients with compensated cirrhosis and PSC, Baveno-VI criteria had a 0% false-negative rate for varices needing treatment, and 30% of EGDs could have been avoided. Patients with PSC should be vaccinated against hepatitis A and hepatitis B if not immune, and those with cirrhosis should be counseled to abstain from alcohol.

Guidance statements
11. All patients with PSC should be considered for participation in clinical trials.
12. In patients not eligible or interested in clinical trials with persistently elevated ALP or GGT, UDCA 13–23 mg/kg/day can be considered for treatment and continued if there is a meaningful reduction or normalization in ALP (GGT in children) and/or symptoms improve with 12 months of treatment.
13. Currently, there is insufficient evidence to recommend the use of oral vancomycin for the treatment of PSC.
14. Patients with PSC with a diagnosis of concurrent AIH should be treated according to the AASLD AIH guidelines.
15. Antibiotics should be used for bacterial cholangitis with consideration for MRCP to rule out relevant strictures.
16. ERCP should be performed for bacterial cholangitis if there is an inadequate response to antibiotics.
17. Upper endoscopy to screen for varices should be performed if the LS is >20 kPa by TE or the platelet count is ≤150,000/mm3.

Surveillance for malignancy
CCA
Clinical practice guidance concerning surveillance of PSC-associated hepatobiliary cancers has varied, especially for CCA, despite the increased recognition of significant long-term risk and impact. This has, in part, been due to (1) a paucity of data regarding the impact of surveillance on clinical outcomes; (2) the heterogeneity of PSC precluding the generalization of surveillance benefit to all patients, specifically those with low risk of CCA such as children with PSC and patients with small-duct PSC; and (3) uncertainty as to how to best risk-stratify patients and individualize surveillance practices. Still, early detection of PSC-associated malignancy can lead to curative surgical intervention.

Although no prospective studies have been performed to support the utility of CCA surveillance in PSC, in a large cohort study, regular surveillance was associated with a higher 5-year survival compared to patients who did not receive regular surveillance (68% vs. 20%, p <0.0061). Although US has a high specificity (94%) for CCA in patients with PSC, it has a low sensitivity (57%) compared to MRI/MRCP (sensitivity 89%, specificity 75%). In addition, a single study suggested that MRI/MRCP is superior to US for CCA.
surveillance in asymptomatic patients with PSC.\textsuperscript{[121]} There is, however, concern related to the long-term effects of repeated gadolinium injections with MRI/MRCP and factors such as added cost, lower widespread availability, and risk of false-positive findings, so their downstream health care burden should be considered.

Carbohydrate antigen 19-9 (CA 19-9), a glycolipid expressed by cancer cells, is the most common serum marker associated with CCA, but limitations include the variability in sensitivity and specificity depending upon the cutoff used. A cutoff value of 129 U/ml demonstrated sensitivity of 78% and specificity of 98%,\textsuperscript{[278]} whereas a cutoff of 20 U/ml demonstrated sensitivity of 78% and specificity of 67%.\textsuperscript{[277]} Importantly, up to one third of patients with PSC with an elevated CA 19-9 may not have CCA\textsuperscript{[279]} and up to 10% of the population do not express CA 19-9.\textsuperscript{[280]} In addition, levels of CA 19-9 between individuals vary by fucosyltransferases (FUTs) 2 and 3 genotype, suggesting that use of different cutoff values based on FUT2 or FUT3 genotype may improve the tumor markers’ sensitivity.\textsuperscript{[281]} Nevertheless, an elevated CA 19-9 may be the only indication of CCA.\textsuperscript{[189]} The combination of MRI/MRCP plus CA 19-9 with a cutoff of 20 U/ml reaches a sensitivity of 100% but has low specificity (38%).\textsuperscript{[277,282]} Similarly, ERCP plus CA 19-9 at a 20-U/ml cutoff reaches 100% sensitivity for diagnosing CCA but with a low specificity of 43%.\textsuperscript{[277]}

When CA is suspected, diagnosis of CCA can be challenging for patients with PSC by cytology alone (Figure 5). Fluorescence in situ hybridization (FISH) analysis employs fluorescently labeled DNA probes to assess for chromosomal aneuploidy (presence of an abnormal number of chromosomes in a cell), which is a hallmark of cancer and may improve the diagnostic accuracy of CCA in PSC. FISH polysomy indicates the presence of five or more cells with gains detected in two or more probes. FISH trisomy (three copies of chromosome 7) or FISH tetrasomy (four copies of all probes) is considered a negative result.\textsuperscript{[283]} A FISH probe set (1q21, 7p12, 8q24, and 9p21 loci) developed specifically for pancreaticobiliary malignancies, including CCA, has a 93% sensitivity and 100% specificity for detection of malignancy.\textsuperscript{[284]} Compared to conventional cytology, FISH polysomy has enhanced sensitivity and similar specificity for CCA detection.\textsuperscript{[284]} It is important to interpret FISH results in the context of each patient scenario, particularly for patients with PSC. Factors that should be considered include serial or multifocal polysomy, presence of suspicious cytology, and elevated CA 19-9.\textsuperscript{[285]} FISH polysomy confirmed at subsequent ERCP (i.e., serial polysomy) as well as polysomy detected in multiple areas of the biliary tree (i.e., multifocal polysomy) are strong predictors of CCA in patients with PSC.\textsuperscript{[285,286]} FISH polysomy in the setting of a dominant stricture also increases the probability of cancer; in a study of 235 patients with PSC, 73% of patients with dominant stricture in the setting of FISH polysomy had CCA.\textsuperscript{[284]} Similarly, FISH polysomy plus a CA 19-9 ≥ 129 U/ml indicates a high likelihood of CCA in patients with PSC without a mass lesion.\textsuperscript{[286,287]}

FISH polysomy and suspicious cytology should be confirmed with a follow-up ERCP with brushings at a 3-month interval (Figure 5). In a patient with PSC with a dominant or severe stricture, serial FISH polysomy with or without suspicious cytology indicates probable CCA. These findings signify biliary tract neoplasm (i.e., HGD or invasive adenocarcinoma). However, these cytopathologic tests cannot distinguish between HGD or invasive adenocarcinoma as HGD harbors cytogenetic abnormalities similar to CCA.\textsuperscript{[288]} Although the natural history of biliary tract dysplasia is not well defined, approximately 70% of patients with PSC with serial polysomy are eventually diagnosed with CCA compared to only 18% of patients with subsequent nonpolysomy results.\textsuperscript{[285]}

**Galbladder cancer**

For gallbladder cancer surveillance, the best imaging approach is unknown. US has a sensitivity and specificity for the detection of gallbladder polyps of 84% and 96%, respectively.\textsuperscript{[289]} CT with oral contrast has a reported sensitivity of only 79% on surgically confirmed gallbladder polyps, though all missed lesions were <5 mm.\textsuperscript{[290]} There are limited data on the ability of MRI to identify gallbladder polyps\textsuperscript{[291]} and none specifically in the context of PSC.

The management of gallbladder polyps ≤8 mm in patients with PSC remains controversial due to the varying rates of neoplasia reported and a reported 40% risk of postoperative complications following cholecystectomy in patients with PSC with advanced disease.\textsuperscript{[177,292]} A review of reported cases in the literature found that a cutoff of 8 mm by US had a sensitivity of 96% and specificity of 53% for neoplasia.\textsuperscript{[191]} Therefore, monitoring of gallbladder polyps ≤8 mm by US every 6 months is a reasonable approach. For gallbladder polyps >8 mm, the decision to perform cholecystectomy versus monitoring with US every 6 months should take into consideration the underlying liver function and the risk of perioperative hepatic decompensation and hepato-biliary infection. Patients with advanced liver disease should be referred to an experienced center, preferably with LT capabilities.

**HCC**

HCC appears to be relatively rare in PSC unless cirrhosis is present.\textsuperscript{[19,293,294]} HCC surveillance should thus be performed in patients with PSC and cirrhosis analogous to patients with cirrhosis unrelated to PSC.\textsuperscript{[295]}
Colon cancer

Although there are no data on the effectiveness of CRC surveillance in PSC-IBD, adherence to surveillance guidelines for CRC in patients with IBD, including those with PSC, has been associated with lower CRC rates.[10,296] Various modalities incorporating high-definition white light endoscopy, chromoendoscopy, and other advanced imaging techniques have been proposed to improve the detection of dysplasia in IBD compared to random biopsies; but there is a lack of consensus on the superiority of any modality.[297–300] CRC surveillance for patients with PSC-IBD should include high-definition colonoscopy with biopsies at 1-year to 2-year intervals starting at the time of PSC-IBD diagnosis.[139] In patients with PSC under age 15 years, CRC is rare; therefore, surveillance should begin at age 15 years.[145] Chromoendoscopy should be added when only standard-definition colonoscopy (640 × 480 pixels) is available. Surveillance of biopsy-proven invisible low-grade colonic dysplasia should include high-definition colonoscopy with chromoendoscopy.

Guidance statement

22. In patients with PSC in whom IBD is diagnosed, high-definition surveillance colonoscopy with biopsies should start at age 15 years and be repeated at 1-year to 2-year intervals to evaluate for colonic dysplasia.

Endoscopic and percutaneous therapy

In addition to bacterial cholangitis that has an inadequate response to medical management, indications for ERCP in patients with PSC may include new-onset or worsening pruritus, unexplained weight loss, worsening serum liver test abnormalities, serum CA 19-9 elevation, or noninvasive imaging worrisome for a relevant stricture or CCA. However, the indication for ERCP must be carefully weighed against the potential risks, and MRI/MRCP should generally be considered prior to ERCP to clarify the need for biliary intervention as well as the potential technical approach. For patients in whom ERCP is indicated but unsuccessful, a repeat attempt (by a more experienced endoscopist if possible), percutaneous drainage, or rendezvous-ERCP should be considered.

Bacterial cholangitis following ERCP occurs in 2%–8% of patients with PSC who undergo ERCP.[272,273] Periprocedure antimicrobial prophylaxis should therefore be administered to patients with PSC undergoing ERCP unless they are already on antimicrobial therapy covering biliary tract microflora.[301] The ideal duration of prophylaxis has not yet been defined but is generally 1–3 days depending on various clinical factors.[118,302]

Intraductal tissue sampling with brushing and/or biopsy should be performed in patients with relevant strictures. Sampling for cytology and FISH analysis should also be considered for patients with PSC undergoing ERCP for other indications, depending on the clinical scenario, given the possibility of unsuspected biliary dysplasia. Further information on this is described in the section on CCA.

Whether or not to perform biliary sphincterotomy/papillotomy in patients with PSC is controversial. In general, and in the absence of contraindications, it should be performed for patients with difficult biliary cannulation or an anticipated need for subsequent ERCPs.[303] Whether or not to perform biliary sphincterotomy/papillotomy should be weighed together with the potential risks, particularly in patients with portal hypertension and/or coagulopathy.

The decision to (1) perform balloon dilation and (2) stenting of a stricture should be made by a multidisciplinary care team, including the endoscopist, based on various individual patient considerations, including the perceived adequacy and durability of response to balloon dilation and ability to return for stent removal within an appropriate time window. When performed, balloon dilation of a biliary stricture should not exceed the diameter of the bile ducts immediately delimiting the stricture. If a plastic biliary stent is placed, it should generally be removed within 4 weeks to minimize the risk of adverse events.[304] The role of self-expanding metallic stents in PSC remains unclear, but their use may be considered in select cases.

Repeat therapeutic intervention for a persistent relevant stricture should be performed if the relevant stricture...
is regarded as a cause of symptoms (cholangitis, pruritus, pain) or significant serum liver test abnormalities. Repeat diagnostic sampling should be serially performed during such procedures to rule out underlying dysplasia. In patients with relevant stricture(s) refractory to endoscopic and/or percutaneous management, referral to an experienced center should be made or LT considered.

Post-ERCP pancreatitis occurs in 1%–9% of patients with PSC undergoing ERCP depending on patient, procedure, and operator factors. Three main options for prophylaxis against post-ERCP pancreatitis exist, each with its respective advantages and disadvantages. Periprocedure rectal administration of 100 mg of indomethacin (or diclofenac) should be considered in all patients undergoing ERCP in the absence of contraindications. Similarly, lactated Ringer’s i.v. solution should be administered periprocedure. However, to what degree PSC-related complications such as portal hypertension, coagulopathy, renal dysfunction, and volume overload may impact the selection of these prophylactic options remains unclear. A third option is placement of a prophylactic pancreatic duct stent, which should be considered anytime the pancreatic duct is accessed or injected.

Guidance statements

23. ERCP may be indicated for the evaluation of relevant strictures as well as new-onset or worsening pruritus, unexplained weight loss, worsening serum liver test abnormalities, rising serum CA 19-9, recurrent bacterial cholangitis, or progressive bile duct dilation. MRI/MRCP should be considered prior to ERCP to clarify the need for biliary intervention and guide the technical approach.

24. Antimicrobial prophylaxis should be administered during the periprocedure period in patients with PSC undergoing ERCP.

25. The choice between biliary balloon dilation with and without stenting should be left to the endoscopist’s discretion. In cases where a plastic biliary stent is placed, the stent should generally be removed within 4 weeks following placement.

Symptom management

Pruritus

Many patients with PSC (30%–60%) suffer from pruritus, or itch, which can be severe and disabling. Both pruritus and fatigue have been shown to impact patients’ health-related quality of life and can lead to social isolation and depression. Similar to pruritus associated with PBC, PSC-associated pruritus is often worse at night and exacerbated by heat.

The pathophysiology of pruritus is not well elucidated. Even in the absence of biliary obstruction, pruritus is common. Many potential pruritogens have been proposed in PSC including serotonin, endogenous opioids, histamine, lysophosphatidic acid, autotaxin, bile salts, TNF-α, gut-derived pruritogens, protease-activated receptor 2, and progesterone metabolites. Candidate pruritogen receptors include the G protein-coupled receptors Takeda G protein-coupled receptor 5 and MAS related GPR family member X4, both of which have been shown to bind to bile acids. However, bile acid levels do not correlate well with itch; and OCA, which decreases levels of circulating bile acids, induces pruritus.

There is no approved treatment for cholestasis-associated pruritus, and UDCA has not been shown to be effective. Treatment options for pruritus are limited, with variable rates of response. The new onset or worsening of itch may indicate benign or malignant biliary obstruction. Once this is ruled out by MRI/MRCP, patients should be advised to avoid the heat and hot baths and use topical emollients and antihistamines. If these measures are ineffective, bile acid sequestrants, such as cholestyramine (4–16 mg/day), taken approximately 20 min before a meal for optimal effect, should be used. Second-line therapies for refractory symptoms include sertraline (100 mg/day), naltrexone (50–100 mg/day), and rifampin (150–300 mg/day). Importantly, rifampin has been associated with hepatotoxicity, hemolytic anemia, renal failure, and thrombotic thrombocytopenic purpura. Bezafibrate along with other PPAR agonists have been reported to improve cholestatic itch, primarily in PBC. In a randomized controlled trial of 74 patients (46 PSC) with moderate to severe cholestatic itch randomized to bezafibrate 400 mg daily or placebo, 45% of patients treated with bezafibrate achieved the primary endpoint of ≤50% reduction of pruritus compared to 11% treated with placebo. However, bezafibrate is not currently approved for use in the United States. For patients unresponsive to these regimens, phototherapy and plasmapheresis have been reported in small case series as being effective; and in rare cases, LT may be indicated.

Fatigue

Fatigue is also quite common in patients with PSC, and its etiology is unclear. Similar to pruritus, fatigue is associated with decreased quality of life and is not correlated with PSC disease severity. Other causes of
fatigue such as hypothyroidism, obstructive sleep apnea, and depression should be excluded and treated appropriately. Lifestyle changes such as regular exercise and improved sleep hygiene may offer some benefit to patients with PSC and fatigue, as also seen in other diseases.

**IBD management**

The clinical course of PSC-IBD is often less aggressive, with decreased hospitalizations and less frequent need for immunosuppression.\(^\text{52,147}\) However, patients with PSC are prone to developing pouchitis\(^\text{148}\) after ileoanal anastomosis, and patients with portal hypertension have an increased risk of peristomal and stomal varices.\(^\text{149}\) Refractory bleeding can be treated with transjugular intrahepatic portosystemic shunt, surgical shunts, embolization, and LT.\(^\text{327}\)

Management of IBD in patients with PSC is similar to that in those without PSC.\(^\text{300}\) A number of studies, including two clinical trials, have examined the effect of anti-TNF-\(\alpha\) antibodies in patients with PSC with IBD and found that they are safe but have little effect on liver biochemistries.\(^\text{174,242,328,329}\) Vedoluzimab is safe and effectively treats IBD in patients with PSC but does not improve liver enzymes.\(^\text{330,331}\)

After LT, a high proportion of patients with IBD will experience variable levels of disease activity that do not always correlate with clinical manifestations.\(^\text{332,333}\) Furthermore, following LT, the increased risk of CRC remains and may be further increased with the use of immunosuppression.\(^\text{334–337}\) In one retrospective study, 23% developed colorectal dysplasia or cancer posttransplant\(^\text{337}\) and a meta-analysis reported a 10 times higher risk compared to individuals transplanted for reasons other than PSC.\(^\text{338}\) Proactive medical management of IBD after transplant is critical due to the increased risk of recurrent PSC (rPSC) associated with poorly controlled or de novo IBD.\(^\text{339}\) Therefore, endoscopic CRC surveillance should continue. Recent small series support the effectiveness and safety of anti-TNF and anti-integrins for IBD treatment after LT.\(^\text{340,341}\)

**Fertility and pregnancy**

PSC affects women of childbearing age, but fortunately, available data suggest that overall maternal and fetal outcomes are similar to those of the general population. PSC has not been associated with increased risk of stillbirth, congenital malformations, fetal loss, or low Apgar scores.\(^\text{342,343}\) However, an increased rate of preterm birth and cesarean section in pregnant patients with PSC has been associated with increased maternal bile acid levels and ALT levels.\(^\text{342,344}\) Pregnancy does...
not appear to alter the course of PSC, but worsening of liver tests during or postpregnancy can occur in 20% and 32%, respectively.[343] De novo pruritus or worsening of pruritus can occur and even lead to elective induction of pregnancy. [345] UDCA is safe in pregnancy and lactation and may be continued in pregnant patients with PSC.[346,347]

Additionally, pregnancy in patients with PSC with portal hypertension has the same risks as pregnancy in patients with portal hypertension from other chronic liver diseases and should be managed accordingly.[347] On the other hand, active IBD is associated with adverse pregnancy outcomes.[343,348]

Patients with PSC should be monitored closely when pregnant with routine blood tests and clinical assessments. In those with suspected biliary obstruction, US is the preferred imaging modality; but MRCP without gadolinium can be safely performed if US is inconclusive.[349] ERCP should be reserved for patients who will likely need an intervention and preferably in the second or third trimester, though relatively low maternal and fetal complications have been reported.[350]

**Nutrition and mineral bone disease in PSC**

Patients with PSC are at an increased risk of protein-energy malnutrition and frailty in advanced liver disease.[351–353] Patients with chronic cholestatic liver disease are at increased risk for fat-soluble vitamin deficiencies because of reduced intestinal absorption. Patients with early PSC have been reported to have deficiencies of vitamins A, D, and E of rates of 40%, 14%, and 2%, respectively; and among those with advanced disease the rates were 82%, 57%, and 43%.[354] Thus, vitamins A, D, and E should be measured and supplemented as needed (Table 4). A 2011 single-center longitudinal cohort study of 237 patients with PSC identified osteoporosis in 15%, a 23.8-fold increased risk compared to population controls. Multivariate analysis identified age ≥ 54, body mass index ≤24 kg/m², and IBD for ≥ 19 years correlating with osteoporosis.[357] In contrast, a recent study of 238 patients with PSC found no correlation between osteoporosis and age, disease duration, or severity of disease but rather a correlation between bone mineral density and bone reabsorption and T helper 17-cell frequency.[358] Bone disease is associated with nontraumatic fractures representing a significant source of morbidity before and after LT as well as reduced quality of life.[359–361] Therefore, all patients with PSC should be screened for metabolic bone disease by bone density measurement at diagnosis and then every 2–3 years in those with normal bone mineral density (Figure 7).[362–364]

**Guidance statements**

26. Bile acid sequestrants should be used as initial therapy for patients with PSC who have pruritus that does not respond to conservative measures such as heat avoidance, emollients, and antihistamines. Alternatives for refractory pruritus include sertraline 100 mg daily, naltrexone titrated to a dose of 50–100 mg daily, and rifampin 150–300 mg twice daily.

27. Management of IBD in patients with PSC is similar to that in those without PSC. Active management of IBD and surveillance of colon cancer should continue in the posttransplant period.

28. Nutritional assessments, including but not limited to biometrics and lipid-soluble vitamin levels, should be performed at PSC diagnosis and yearly thereafter with nutritional intervention and vitamin supplementation as needed.

29. Bone density examinations should be performed to exclude osteopenia or osteoporosis at diagnosis and at 2-year to 3-year intervals thereafter based on risk factors.

**LT for cirrhosis/cholangitis/CCA**

PSC accounts for approximately 5% of LTs annually in the United States.[365,366] Typical transplant indications for PSC are life-threatening complications of cirrhosis and portal hypertension, intractable pruritus, recurrent bacterial cholangitis,[176,367–370] and early-stage CCA.[155,371] Patients with PSC with cirrhosis and at least two admissions to the hospital within a 1-year period for acute cholangitis with a documented bloodstream infection or evidence of sepsis including hemodynamic instability requiring vasopressors qualify for MELD exceptions.[372] In addition, patients with PSC with CCA diagnosed by the presence of a malignant-appearing stricture and cytology/biopsy, a CA 19-9 >100 U/ml in the absence of cholangitis, aneuploidy, or a hilar mass <3 cm in radial diameter can qualify for MELD exception points.[372] Alternatively, patients with PSC may benefit from receiving a living donor graft.[176,373] Patient and graft survival in PSC are comparable with those transplanted for other liver diseases.[374]

In addition, transplantation results in substantial improvement in all aspects of quality of life,[375–377] although fatigue persists in a significant proportion of female patients.[378] Given the potential risk of biliary strictures and CCA in the remnant duct, Roux-en-Y choledochojejunostomy has been the preferred method for biliary...
<table>
<thead>
<tr>
<th>Vitamin</th>
<th>Clinical symptoms</th>
<th>Recommend daily doses (children)</th>
<th>Recommend daily doses (adults)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Repletion</td>
<td>Maintenance</td>
<td>Repletion</td>
</tr>
<tr>
<td>Vitamin A</td>
<td>Night blindness, xerophthalmia</td>
<td>5000–10,000 IU daily</td>
<td>1500–5000 IU daily</td>
<td>5000–100,000 IU daily (\times 2) weeks</td>
</tr>
<tr>
<td>Vitamin E</td>
<td>Neuropathy, ataxia, progressive neuromuscular disorder, hemolytic anemia</td>
<td>100–200 mg daily</td>
<td>15–25 mg daily</td>
<td>200–2000 mg daily</td>
</tr>
<tr>
<td>Vitamin K</td>
<td>Hypoprothrombinemia, bone disease (impaired osteoblast function)</td>
<td>2–5 mg i.v. (\times 3) days</td>
<td>2–5 mg daily</td>
<td>2.5–10 mg daily</td>
</tr>
</tbody>
</table>

Note: Water-miscible formulas are recommended for supplementation.

Abbreviation: INR, international normalized ratio.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th>Serum 25(OH)D &lt; 12 ng/ml</th>
<th>Serum 25(OH)D 12–20 ng/ml</th>
<th>Serum 25(OH)D 20–30 ng/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin D(^d)</td>
<td>Osteomalacia,(^a) osteoporosis,(^b) Rickets,(^c) tetany in children</td>
<td>4000–8000 IU daily</td>
<td>400–2000 IU daily</td>
<td>800 IU daily</td>
</tr>
</tbody>
</table>

\(^a\)Defective mineralization of the preformed osteoid occurs in both adults and children.
\(^b\)Bone mineral density T-score < 2.5 present in 4%–10% of patients with PSC.
\(^c\)Defective mineralization of the growth plate in growing children.
\(^d\)Vitamin D\(_3\) should be used for treatment and supplementation due to its greater bioavailability and affinity for vitamin D–binding protein.
reconstruction.\textsuperscript{379} Still, due to difficulties in managing biliary strictures in rPSC, there is a trend by some centers to perform duct-to-duct anastomosis if the bile duct appears normal or in the absence of HGD at the time of transplantation.\textsuperscript{380–382} Duct-to-duct anastomosis appears to be associated with a lower incidence of posttransplant cholangitis and does not affect overall graft outcomes.\textsuperscript{380,381}

Posttransplant complications in patients with PSC are similar to those in patients transplanted for other indications with the exception that PSC is associated with more frequent and steroid-refractory allograft rejection.\textsuperscript{369,370,383,384} Hence, an unanswered question is whether patients transplanted for PSC would benefit from modified immunosuppression protocols, such as prolonged dual or triple immunosuppression therapy, delayed steroid withdrawal, or the introduction of regimens that treat IBD.\textsuperscript{374,385,386}

\textbf{rPSC}

rPSC occurs in 10\%–37\% of transplanted recipients at a mean of 0.5–5 years post-LT.\textsuperscript{367,369,373,387,388} The diagnostic criteria of rPSC include a confirmed diagnosis of PSC before transplant, a cholestatic pattern of liver enzyme elevations, cholangiography demonstrating multifocal nonanastomotic biliary strictures, and an absence of chronic ductopenic rejection, hepatic ischemia, or donor–recipient blood type incompatibility, which all

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{bone_disease.png}
\caption{Bone disease management in PSC. In patients with PSC with normal serum vitamin D levels who have osteopenia or osteoporosis, vitamin D (2000 IU/day) and calcium (1–1.5 g/day) supplementation should be administered. Patients with osteoporosis should additionally receive bisphosphonate therapy orally or parenterally (in the presence of esophageal varices). Osteopenia: Characterized by bone mineral density T-score standard deviation of −2.5 to −1. Osteoporosis: Characterized by bone mineral density T-score standard deviation ≤−2.5.}
\end{figure}

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{risk_factors.png}
\caption{Risk factors for CCA. A ranked list of risk factors and associated ORs for iCCA and pCCA or dCCA is presented with a list of potentially actionable mutations for iCCA or pCCA/dCCA. Abbreviations: BRCA1/2, breast cancer gene 1/2; ERBB2, Erb-B2 receptor tyrosine kinase 2; HER2, human EGF receptor 2; MSI, microsatellite instability; NRTK, nonreceptor tyrosine kinase; TMB, tumor mutational burden.}
\end{figure}
occur at least 90 days after LT. However, the clinical picture of rPSC, chronic rejection, and biliary complications overlap, renders a diagnosis of rPSC challenging.

Risk factors for rPSC include male sex, extended-criteria grafts, steroid-free antithymocyte globulin induction protocols, primary immunosuppression with tacrolimus, and allograft rejection. 

Poorly controlled or de novo IBD is also a risk factor for rPSC. In contrast, pretransplant colectomy may be protective. Living donor LTs do not appear to increase the risk of rPSC even with first-degree relative donors.

The impact of rPSC on graft and patient survival remains incompletely delineated. The rate of retransplantation for rPSC overall has been reported to be 12.4% at 10 years, which is higher than the rate of 8.5% for PBC specifically because the rate of recurrent disease is greater than that for PBC. Given the negative impact of rPSC in the allograft, LT should not be offered without clear indications of a benefit.

Guidance statements

30. LT should be considered in all patients with PSC and complications of end-stage liver disease, recurrent cholangitis, intractable pruritus, or early-stage hepatobiliary cancers.

31. Patients with elevated liver enzymes after transplant should undergo histological and cholangiographic assessments to distinguish rPSC from allograft rejection and/or biliary complications.

CCA

The following guidance is applicable for the diagnosis and management of CCA in patients with or without underlying PSC. CCAs are heterogeneous cancers with cholangiocyte differentiation along the intrahepatic or extrahepatic biliary tree (Figure 8). CCAs are classified into three distinct subtypes based on their anatomic location. Intrahepatic CCA (iCCA) arises proximal to second-order bile ducts within the hepatic parenchyma, perihilar CCA (pCCA) arises between second-order bile ducts and the cystic duct insertion, and distal CCA (dCCA) arises in the common bile duct below the cystic duct insertion.

Epidemiology and risk factors

The true incidence and mortality rates of each CCA subtype remain ambiguous due to misclassification of pCCA as iCCA in large databases, as well as collective grouping of pCCA and dCCA as extrahepatic CCA. There are significant geographic variations in the epidemiology of CCA. The age-standardized incidence rate (ASIR) per 100,000 of CCA is significantly higher in southeast Asia (ASIR 100 among men in northeast Thailand) where liver fluke infection (Clonorchis sinensis and Opisthorchis viverrini) is endemic. In the Western world, CCA is relatively rare, with an ASIR of 0.3–3.4. An increase in iCCA incidence has been reported, whereas rates of pCCA and dCCA have remained stable over the past several decades. Similarly, mortality rates of iCCA have increased globally from 2000 to 2014 (1.5–2.5/100,000 in men and 1.2–1.7/100,000 in women), with the highest rates reported in Hong Kong, western Europe, and Australia. Mortality rates of pCCA/dCCA, meanwhile, have decreased, with rates below 1/100,000 in most countries. These trends need to be interpreted with caution because prior versions of the ICD did not have a separate code for pCCA and prior versions of the ICD-Oncology (ICD-O) cross-referenced pCCA to iCCA.

The forthcoming versions of both the ICD and the ICD-O will have separate codes for iCCA, pCCA, and dCCA.

Multiple risk factors, particularly those linked to chronic biliary inflammation, are associated with CCA, with some conferring a higher risk than others.
Resectable Surgery
Adjunctive chemotherapy

Unresectable

Single lesion ≤ 2 cm
Consider referral to a liver transplant center
Decompenated liver function
and/or ECOG > 2
Best supportive care
Systemic therapy
- First line: gemcitabine/cisplatin
- Second line: FOLFOX
- Clinical Trials: next generation sequencing, targeted therapy, immunotherapy

Preserved liver function,
ECOG ≤ 2
Liver transplantation following neoadjuvant therapy

Single lesion > 2 cm and/or presence of intra- or extrahepatic metastasis
Decompenated liver function
and/or ECOG > 2
Preserved liver function,
ECOG ≤ 2

Best supportive care

*Child's Pugh A without ascites

For liver limited disease with excellent response to systemic chemotherapy, consider referral for surgical resection or to a liver transplant center with a specific transplant protocol for iCCA.
Furthermore, some risk factors are shared by the different subtypes, whereas others are subtype-specific (Figure 8). For instance, Caroli’s disease (ORs, 38 and 97 for iCCA and pCCA, respectively) and choledochal cysts (ORs, 27 and 35 for iCCA and pCCA, respectively) confer a high risk of CCA regardless of subtype.\(^{409,410}\) Meanwhile, cirrhosis and viral hepatitis (hepatitis B and C) have a stronger association with iCCA.\(^{409}\) Hepatolithiasis is primarily associated with iCCA, whereas choledocholithiasis is linked to pCCA/dCCA.\(^{411}\) The geographic distribution of risk factors varies as well because infection with liver flukes occurs primarily in Southeast Asia, whereas PSC is primarily seen in Western countries.\(^{400}\) Although there are well-known risk factors for CCA, it is important to note that in the Western world almost half of diagnosed cases are sporadic and have no identifiable risk factor.\(^{400}\)

### iCCA

#### Diagnosis

iCCA may be an incidental finding in up to one third of patients\(^{412}\) and is often diagnosed during routine surveillance imaging for HCC in patients with cirrhosis. Symptoms, such as jaundice or abdominal pain, are typically associated with more advanced disease. Serologic assessment includes routine liver tests as well as CA 19-9, the primary biomarker used in CCA detection. CA 19-9 has subar specificity for CCA detection because it is elevated in several benign and malignant conditions, including other causes of biliary obstruction and, therefore, by itself is not sufficient to diagnose CCA. However, a significantly elevated CA 19-9 level (≥ 1000 U/ml) may indicate the presence of metastatic disease.\(^{413}\) Imaging modalities such as multiphasic CT and MRI are essential in assessment of the primary mass, detection of metastases, and disease staging. MRI may provide better assessment of the mass, whereas CT is superior for detection of vascular enhancement and assessment of resectability.\(^{414}\) HCC surveillance in patients with cirrhosis may facilitate earlier iCCA diagnosis, albeit distinctly between HCC and iCCA can be challenging in cirrhosis.\(^{415}\) The typical imaging feature of iCCA is initial rim or peripheral enhancement in the arterial phase followed by progressive homogenous enhancement of the tumor in the delayed phases.\(^{416,417}\) Contrast-enhanced US, although insufficient as the sole diagnostic modality, may be considered when CT or MRI is inconclusive.\(^{415}\) Positron emission tomography (PET) scanning is typically not used in primary tumor diagnosis for iCCA due to limited accuracy; however, PET does have reasonable performance in detection of lymph node (LN) and distance metastasis.\(^{418,419}\) Definitive diagnosis of iCCA requires histopathological assessment of a core needle biopsy specimen.

#### Surgical resection

Liver resection is the recommended treatment option for a solitary iCCA without extrahepatic involvement in patients with adequate functional liver volume (Figure 9A). Following iCCA diagnosis, patients should be referred to a hepatobiliary surgeon for consideration of resection. The goal of surgery for iCCA is to achieve an R0 (negative margin) resection. In general, surgery involves resection of one or more liver segments and a portal lymphadenectomy. Unfortunately, <40% of patients are resectable at diagnosis.\(^{420}\) Some cases may require major vascular resection and reconstruction because these tumors tend to abut the hepatic veins and major portal structures. Laparoscopic liver surgery is a safe approach in patients with hepatic malignancies,\(^{421}\) but anatomic considerations may necessitate open resection. In patients with cirrhosis, decision for surgery also depends on the presence of portal hypertension. Decompensated cirrhosis and/or portal hypertension are contraindications for surgical resection, and the severity of underlying fibrosis may preclude more extensive resections due to concerns for inadequate residual hepatic reserve.

LN involvement is an important predictor of recurrence after resection.\(^{422}\) In general, metastatic LNs beyond the hepatoduodenal and gastrohepatic ligament are contraindications for surgery, and upfront chemotherapy is preferred. In some cases, “rescue” surgery after chemotherapy can be offered; however, this decision needs to be personalized. The role of neoadjuvant therapies for downstaging of iCCA is not well defined. Although neoadjuvant therapy does not affect the morbidity and mortality of surgery, it may allow resection in some patients with locally advanced iCCA who are initially deemed unresectable.\(^{423,424}\)

At present, liver surgery performed in large hepatobiliary centers has a low morbidity and mortality.\(^{425}\)
The median overall survival (OS) after resection for iCCA is reported to be ~40 months, with a 5-year OS around 25%–70%. Resected patients exhibit a 50%–70% recurrence risk, with a median time to recurrence of 2 years. Importantly, most recurrences (60%) after resection occur in the liver; and in some cases, a second liver resection can be performed to increase survival.

The BILCAP study, a Phase 3 randomized controlled trial of 6 months of capecitabine versus observation following surgical resection (43 iCCA, 65 pCCA, 76 dCCA), found a significant improvement in OS with capecitabine based on protocol-specified sensitivity analysis adjusted for nodal status, disease grade, and sex. Based on these data, adjuvant capecitabine following resection for CCA has become standard practice.

The median overall survival (OS) after resection for iCCA is reported to be ~40 months, with a 5-year OS around 25%–70%. Resected patients exhibit a 50%–70% recurrence risk, with a median time to recurrence of 2 years. Importantly, most recurrences (60%) after resection occur in the liver; and in some cases, a second liver resection can be performed to increase survival.

The BILCAP study, a Phase 3 randomized controlled trial of 6 months of capecitabine versus observation following surgical resection (43 iCCA, 65 pCCA, 76 dCCA), found a significant improvement in OS with capecitabine based on protocol-specified sensitivity analysis adjusted for nodal status, disease grade, and sex. Based on these data, adjuvant capecitabine following resection for CCA has become standard practice.

Guidance statements

37. Surgical resection is the treatment of choice for patients with a single iCCA nodule in a resectable location without evidence of metastatic disease and who have adequate functional liver volume.
38. Patients diagnosed with iCCA should be referred to a center with surgical expertise in hepatobiliary malignancies.
39. Adjuvant capecitabine should be considered for all patients with CCA.

LT for iCCA

Early studies evaluating LT in iCCA demonstrated poor OS and recurrence-free survival (RFS) of 18%–25% after 5 years. Despite iCCA being considered a formal contraindication for LT by many, evidence is emerging that select patients with unresectable, liver-limited iCCA may benefit. Multicenter retrospective analysis of patients with incidental iCCA on transplant explant pathology demonstrated a 5-year OS of 62% with a 16.7% risk of recurrence for small (≤2 cm) solitary iCCA. The initial cohort was subsequently expanded with data from 17 international transplant centers, demonstrating that LT in patients with a solitary iCCA ≤2 cm results in a 5-year OS of 65%. A subgroup analysis of patients with well or moderately differentiated tumors ≤3 cm demonstrated 5-year survival of 61% compared to 42% with more advanced disease. Although 2 cm may seem a low threshold for iCCA detection, a later multicenter cohort of patients with incidental iCCA demonstrated a 5-year RFS of 74% tumor with a cumulative diameter of 2–5 cm. Larger tumor size and absence of pretransplant locoregional therapy (LRT) impute the greatest risk for recurrence. Thus, promising data exist for LT in patients with small iCCA that are unresectable due to underlying liver disease, and prospective clinical trials are in progress to further evaluate this option.

Neoadjuvant therapy plus LT for patients with iCCA has also been evaluated in limited prospective case series with promising results. Patients with biopsy-proven, unresectable, locally advanced iCCA with tumor stability on chemotherapy (gemcitabine + cisplatin [gem/cis] or carboplatin) for at least 6 months underwent LT. Initial data demonstrated an OS of 83.3% and an RFS of 50% at 5 years, and patients had a median cumulative tumor diameter of 14.3 cm. Although limited by patient number, this study showcases feasibility and underscores the need for more prospective evaluation of neoadjuvant and multimodal pretransplant therapies in the setting of LT. Biologic tumor characteristics affect success after LT. For patients with more advanced liver-limited iCCA who have favorable response to chemotherapy, consideration may be given for referral to a transplant center with research protocols to evaluate LT for iCCA.

LRT

LRT or liver-directed therapeutic options include transarterial chemoembolization (TACE), drug-eluting bead TACE (debTACE), transarterial bland embolization (TAE), transarterial radioembolization (TARE), and external beam radiation therapy. LRT is often considered for patients with liver-limited, locally advanced, unresectable iCCA. However, to date, no randomized controlled trials have compared different forms of LRT for iCCA. In patients with localized, unresectable iCCA, TACE and debTACE are overall well tolerated and achieve a median survival of 12–15 months. Retrospective comparative analysis of TACE and debTACE demonstrated improved OS with debTACE compared to TACE (11.7 months versus 5.7 months). The efficacy of TARE using yttrium-90 microspheres has also been modest in unresectable locally advanced iCCA. In small series of patients with unresectable iCCA, TARE has median survival durations of 9–22 months. Multicenter retrospective analysis of LRT (TACE, debTACE, TAE, TARE) in patients with advanced iCCA (n = 198) demonstrated that OS (median OS, 13.2 months) did not differ based on type of LRT. Eastern Cooperation Oncology Group (ECOG) performance status has a significant impact...
on survival following LRT; patients with an ECOG of 0 have significantly improved survival compared to those with ECOG ≥ 1.\textsuperscript{[444–446,448]}

Advances in radiation therapy such as stereotactic body radiation therapy (SBRT) and delivery of charged particles, such as proton beam, have facilitated delivery of targeted radiation therapy to the tumor while sparing nonmalignant tissues.\textsuperscript{[449,450]} A single-center retrospective analysis of SBRT in patients with locally advanced iCCA with median tumor size 7.9 cm reported a median OS of 30 months, with higher doses correlating with improved OS.\textsuperscript{[451]} In a multi-institutional Phase 2 study of 37 patients with localized, unresectable iCCA, the median OS was 22.5 months with a 2-year local control rate of 94%.\textsuperscript{[449]}

The addition of chemotherapy may enhance efficacy of LRT. A Phase 2 trial of hepatic arterial infusion of fluorouridine plus systemic gem/cis in patients with unresectable iCCA reported a 1-year OS of 89% with a median OS of 25 months.\textsuperscript{[452]} There are ongoing studies evaluating the combination of systemic chemotherapy plus SBRT (AB7-07 and EudraCT 2014-003656-31).

### Guidance statement

41. Data are insufficient to recommend LRT as a standard therapy for locally advanced unresectable iCCA.

### Diagnosis

#### Perihilar and distal CCA

Painless jaundice is the most common presentation of pCCA and dCCA. The primary modalities used in the diagnosis of pCCA/dCCA are multiphasic contrasted CT, MRI/MRCP, and ERCP.\textsuperscript{[453]} MRI/MRCP has enhanced diagnostic capability compared to CT for assessment of biliary neoplastic invasion and for distinguishing between benign and malignant causes of hilar obstruction, with a sensitivity and specificity of 87% and 85%, respectively.\textsuperscript{[454]} CA 19-9 level should be obtained, but caution should be employed in interpretation for patients with biliary obstruction. IgG4 levels can also be helpful in excluding IgG4 sclerosing cholangiopathy. In patients with suspected pCCA/dCCA, ERCP can delineate the biliary anatomy and allow for acquisition of biliary brushings for cytology and FISH analysis. Positive biliary cytology or a biliary biopsy positive for adenocarcinoma confirms a diagnosis of pCCA or dCCA.\textsuperscript{[455]} Although conventional biliary cytology has a high specificity (~97%), the sensitivity for detection of CCA is limited, with one meta-analysis demonstrating a pooled sensitivity of 43%.\textsuperscript{[455]} FISH analysis has enhanced sensitivity for CCA detection.\textsuperscript{[284]} Transperitoneal biopsies must be avoided in patients with pCCA who are potential LT candidates because this will exclude them from transplant.

Endoscopic US (EUS) allows for a detailed examination of the extrahepatic bile duct and tissue acquisition through fine-needle aspiration (FNA). EUS-FNA has a higher sensitivity for detection of dCCA compared to pCCA.\textsuperscript{[456]} ERCP with brushings and EUS should be part of the diagnostic workup of dCCA. EUS-guided tissue acquisition of pCCA should be avoided if LT is being considered due to the potential risk of tumor dissemination.\textsuperscript{[457]} EUS-FNA of LN, on the other hand, can effectively identify the presence of malignant LN in patients with all three CCA subtypes.\textsuperscript{[458]} In patients being evaluated for LT, nodal metastasis is a contraindication to LT, and EUS-FNA of LN is often performed to exclude these patients from LT. Notably, there are no clearly identified LN morphologic criteria to accurately predict the presence of nodal malignancy.\textsuperscript{[459]} A PET scan may play a role in the staging of CCA because it can be used for detection of LN and distant metastasis.\textsuperscript{[418,419]}

#### Surgical resection

Surgery is the recommended treatment option for patients diagnosed with early-stage pCCA, normal liver function, and sufficient functional liver volume (Figure 9B). Notably, transplant is preferred over resection in all cases of PSC. Surgical resection in this setting is complex; therefore, patients should be referred to a center with surgical expertise in hepatobiliary malignancies for assessment. Even in experienced centers, the morbidity after this intervention is high, and mortality has been reported up to 15% in the first 90 days, especially for more extensive resections.\textsuperscript{[460–463]} In patients with resectable pCCA, preoperative biliary drainage of the future remnant lobe(s) improves postsurgical outcomes, particularly
in extended liver resections, and is recommended if the patient is jaundiced.\cite{462-464} Surgery is contraindicated in the presence of intrahepatic or extrahepatic metastases or extraregional LNs (beyond the portal triad); as such, no survival benefit will be obtained. The longitudinal extent of the tumor is vital. If both the distal and proximal common bile ducts are involved, surgery is typically not recommended due to substantial increases in operative morbidity and mortality.

The goal of surgery is to achieve an R0 resection, and resection generally consists of a major hepatectomy (at least three segments) plus the caudate lobe, extrahepatic bile duct resection, reconstruction with an hepaticojejunostomy, and portal lymphadenectomy. In some cases, vascular resection and reconstruction of the portal vein are required to achieve an R0 resection.\cite{465} Inclusion of a pancreaticoduodenectomy has been reported in Asia for patients with more extensive disease.\cite{466-468} Following surgical resection for pCCA or dCCA, preoperative endoscopic biliary drainage of the remnant liver is recommended if biliary obstruction is present.\cite{472} The risk of recurrence is around 80%, mostly in the first 2 years.\cite{472} The main risk factors for a poor outcome are R1 resection (microscopic residual disease), which can be found in up to 50% of cases, and positive portal LNs.

Surgical resection of dCCA consists of a pancreaticoduodenectomy with resection of the bile duct and gallbladder, the head of the pancreas, and the first part of the duodenum (Figure 9C). The 5-year OS after surgery for dCCA is around 30%--45%,\cite{461,469-471} though the risk of recurrence is around 80%, mostly in the first 2 years. The primary predictors of poor OS include increasing age, high LN ratio, poor tumor differentiation, and R1 resection.\cite{474} Following surgical resection for pCCA or dCCA, 6 months of adjuvant capecitabine is recommended.\cite{431}

Neoadjuvant chemoradiation and LT

Poor historic OS and RFS following LT for pCCA led to this cancer being considered a contraindication for LT; however, strict patient selection criteria in conjunction with combining neoadjuvant chemoradiation therapy with LT has led to an increasingly wide acceptance of LT in pCCA. Currently, the Organ Procurement and Transplantation Network (OPTN) recognizes early pCCA as an indication for LT.\cite{372,475,476}

The neoadjuvant therapy plus LT protocol selects patients with early-stage (≤3 cm in radial diameter) unresectable (due to underlying liver disease or mass location) pCCA without intrahepatic or extrahepatic metastasis. A positive biliary biopsy or positive biliary cytology confirms diagnosis of CCA. In the absence of positive cytology or a positive biliary biopsy, any one of the following diagnostic criteria are definitive for pCCA: (1) malignant-appearing stricture and CA 19-9 >100 U/mL (in the absence of cholangitis or unstented obstructive jaundice), (2) malignant-appearing stricture with suspicious cytology and/or FISH polysomy, or (3) perihilar mass with imaging features of CCA. Pretransplant percutaneous tumor biopsy, EUS-guided FNA, and surgical violation of the tumor plane are contraindications to LT due to risk of peritoneal seeding. LN metastases are also considered to be a contraindication to LT. All patients should undergo EUS-FNA to assess for nodal metastasis prior to initiation of neoadjuvant therapy.

The traditional neoadjuvant therapy includes external beam radiation plus concomitant 5-fluorouracil (5-FU) and brachytherapy followed by maintenance capecitabine until transplantation.\cite{477,478} Following completion of neoadjuvant chemoradiation, OPTN policy is for patients to undergo staging laparoscopy prior to LT.\cite{479}

Single-center data demonstrate OS and RFS as high as 82% after LT.\cite{480-485} These initial data were confirmed by a multicenter study from 12 transplant centers in the United States demonstrating 65% OS and 78% RFS at 5 years following LT.\cite{486} Among patients who entered the protocol (n = 287), 71 dropped out primarily due to tumor progression (n = 23) or positive staging (n = 40). Predictors of pretransplant dropout include CA 19-9 levels ≥500 U/mL, tumor radial diameter ≥3 cm, and MELD score ≥20.\cite{481} Some disparities in LT outcomes for pCCA have been attributed to underlying liver disease etiology; outcomes are more favorable for PSC-associated pCCA, likely due to earlier detection of CCA in patients with PSC undergoing routine surveillance.\cite{478}
Systemic therapy

Although surgery is the definitive treatment for CCA, the majority of patients present with disease that is not amenable to resection or transplant.\(^{[397]}\) In these situations, chemotherapy is the traditional approach and remains palliative in nature with a dismal prognosis.\(^{[487]}\) Gem/cis chemotherapy remains the standard of care for advanced biliary tract cancers based on the ABC-02 study.\(^{[488]}\) However, this combination only resulted in a median progression-free survival (PFS) of 8 months and a median OS of 11.7 months. The combination of 5-FU, oxaliplatin, and irinotecan did not demonstrate any significant improvement in 6-month PFS compared to gem/cis in a randomized Phase 2 study.\(^{[489]}\) A single-arm Phase 2 study of gem/cis plus nab-paclitaxel showed a median OS of 19.4 months and an overall response rate (ORR) of 45%, leading to an ongoing randomized Phase 2 trial (SWOG-1815).\(^{[490]}\)

Retrospective data looking at second-line therapy options after progression on gem/cis have demonstrated a median PFS in the 2-month to 3-month range.\(^{[491–493]}\) The ABC-06 study demonstrated significant improvement in median OS with 5-FU and oxaliplatin (FOLFOX) with active symptom control to active symptom control alone,\(^{[419]}\) but the numerical difference was marginal (5.3 vs. 6.2 months). FOLFOX is now viewed as the gold standard for second-line therapy in advanced biliary tract cancers, but clearly, better therapies are needed for refractory disease.

Over the past decade, there has been significant progress made in understanding the oncogenic drivers and relevant signaling pathways in CCA.\(^{[494]}\) With the advent of next-generation sequencing, relevant targetable alterations have been identified that have helped accelerate drug development in this disease. Up to 40% of CCAs may have molecular alterations for which there are Food and Drug Administration (FDA)–approved drugs or targeted therapies in clinical trial. The genomic landscape of iCCA includes FGF receptor 2 (FGFR2) fusions (10%–15%), isocitrate dehydrogenase (IDH) mutations (15%–20%), and B-raf proto-oncogene (BRAF) mutations (3%–7%). pCCA and dCCA, on the other hand, have a higher rate of EGF receptor alterations (10%–15%).\(^{[495,496]}\)

The FIGHT-202 study investigated the efficacy of pemigatinib, an oral FGFR inhibitor, in patients with CCA with FGFR2 fusions.\(^{[497]}\) This single-arm, Phase 2 study enrolled 146 patients and demonstrated an ORR of 35.5% in a refractory patient population. This drug was well tolerated, and the median PFS was notably 6.9 months. Based on these data, the FDA approved pemigatinib for patients with CCA with FGFR2 fusions, making this the first drug to receive FDA approval for this disease. Subsequently, infigratinib received FDA approval, and futibatinib has shown promise in patients who are FGFR2 fusion–positive. Investigations of all three of these agents in the front-line setting in lieu of gem/cis chemotherapy are ongoing.\(^{[498,499]}\) Further support for molecular profiling in CCA has come from other biomarker-driven studies testing drugs such as ivosidenib, an oral IDH inhibitor, and dabrafenib/trametinib, a BRAF/mitogen-activated protein kinase kinase inhibitor combination.\(^{[500,501]}\) Ivosidenib received FDA approval for patients with previously treated, locally advanced, or metastatic IDH1 mutant CCA.\(^{[502]}\)

Immunotherapy for CCA has thus far shown limited efficacy outside of the rare microsatellite instability high phenotype. The KEYNOTE-158 study demonstrated an ORR of 5.8% with single agent pembrolizumab, a programmed death-ligand 1 (PD-L1) inhibitor, in patients with biliary tract cancers.\(^{[503]}\) A multicenter study investigating the activity of nivolumab in CCA had an intriguing ORR of 22% on investigator review, but with central review of response, this dropped to 11%.\(^{[504]}\) Hope remains for potentiating the immune response by combining checkpoint inhibitors with other agents, including gem/cis. Early data from Korea combining durvalumab, another PD-L1 inhibitor, with gem/cis are promising, and an ongoing global study will better elucidate the potential for immunotherapy in this disease.\(^{[505]}\)

Guidance statements

48. LT following neoadjuvant therapy should be considered for patients with pCCA (≤3 cm in radial diameter) that is unresectable or arising in the setting of PSC.

49. In patients with pCCA being evaluated for LT, EUS-FNA of regional LNs should be performed to exclude patients with metastases before neoadjuvant therapy is initiated. Operative staging after completion of neoadjuvant therapy and before LT to assess regional hepatic LN involvement and peritoneal metastases is required.
FUTURE DIRECTIONS AND AREAS OF ADDITIONAL RESEARCH

Areas for additional research and focus that remain barriers to advancements in the treatment of PSC and CCA include the following:

1. Prospective natural history studies of diverse patient populations of PSC for the development of validated biomarkers, which can serve as surrogate markers of clinical outcomes for use in clinical trials.

2. Development of a PSC-specific tool that accurately measures patient-reported outcomes and encompasses the entire patient experience, including but not limited to abdominal pain, pruritus, and fatigue.

3. Development and validation of new molecular and imaging technologies for the diagnosis and risk stratification of CCA in the presence and absence of PSC.

4. Further profiling of CCA to improve the understanding of the molecular basis and heterogeneity of these tumors with the ultimate goal of providing personalized therapies.

ACKNOWLEDGMENTS

The authors are grateful for the valuable contributions of the AASLD Practice Guideline Committee (PGC), particularly Anjana A. Pillai and Daniel S. Pratt. Members of the PGC include Elizabeth C. Verna (chair), George Ioannou (chair), Rabab Ali, Scott W. Biggins, Roniel Cabrera, Henry Chang, Michael F. Chang, Po-Hung Chen, Kathleen Corey, Archita Parikh Desai, Albert Do, David S. Goldberg, Saul J. Karpen (board liaison), W. Ray Kim (board liaison), Lindsay King, Cynthia Levy, Jeff McIntyre, Jessica L. Mellinger, Anthony J. Michaels, Andrew Moon, Mindie H. Nguyen, Nadia Ovchinsky, Anjana A. Pillai, Daniel S. Pratt, Elizabeth Rand, Hugo R. Rosen, Adrienne Simmons, Ashwani K. Singal, Christopher J. Sonnendorf, Matthew J. Stotts, Puneeta Tandon, and Lisa B. VanWagner.

AUTHOR CONTRIBUTIONS

All authors contributed to the conceptualization, drafting, and revising of the work and gave final approval.

FUNDING INFORMATION

Funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases.

CONFLICT OF INTEREST

Dr. Bergquist advises Ipsen and received grants from Gilead. Dr. Bowlus received grants from Gilead, Bristol-Myers Squibb, GlaxoSmithKline, Mirum, Genkyotex, Boston Scientific, Intercept, Target, Novartis, BiomX, CymaBay, Genfit, COUR and Pliant. Dr. Assis received grants from Gilead, Dr. Sapiochin consults and advises Integra. He consults and received grants from Roche. He consults for AstraZeneca, Novartis and Evidera. Dr. Forman received grants from Gilead, CymaBay and Mirum. Dr. Deneau consults for Gilead, HighTide and Mirum. Dr. Shroff advises and is on the speakers’ bureau for Servier. She advises and received grants from Merck and QED. She consults for SYROS. She advises AstraZeneca, Boehringer Ingelheim, Genentech, CAMI, Clovis, Incyte and Zymeworks. She received grants from Bayer, Bristol-Myers Squibb, Exelixis, IMV, LOXO, Novocure, NUCANA, Pieris, Rafeal, Seagen and Taiho. Dr. Ilyas consults for AstraZeneca. Dr. Tabibian consults for Olympus.

ORCID

Christopher L. Bowlus https://orcid.org/0000-0002-3906-6811
Mark Deneau https://orcid.org/0000-0003-0459-9404
Sumera I. Ilyas https://orcid.org/0000-0002-2709-3003
Mercedes Martinez https://orcid.org/0000-0001-6128-0155

REFERENCES


279. Sinakos E, Saenger AK, Keach J, Kim WR, Lindor KD. Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not


323. Bloomer JR, B...


